Cell therapies in the clinic

Lily Li-Wen Wang1,2,3 | Morgan E. Janes1,2,3 | Ninad Kumbhojkar1,2 | Neha Kapate1,2,3 | John R. Clegg1,2 | Supriya Prakash1,2 | Mairead K. Heavey4 | Zongmin Zhao1,2 | Aaron C. Anselmo4 | Samir Mitragotri1,2

1John A. Paulson School of Engineering & Applied Sciences, Harvard University, Cambridge, Massachusetts, USA
2Wyss Institute for Biologically Inspired Engineering, Boston, Massachusetts, USA
3Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
4Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

Correspondence
Aaron C. Anselmo, Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599.
Email: aanselmo@email.unc.edu

Samir Mitragotri, John A. Paulson School of Engineering & Applied Sciences, Harvard University, Cambridge, MA 02138.
Email: mitragotri@seas.harvard.edu

Funding information
National Institutes of Health, Grant/Award Numbers: 1R01HL143806-01, R35GM137898; National Science Foundation; U.S. Department of Defense, Grant/Award Number: W81XWH-19-2-0011

Abstract
Cell therapies have emerged as a promising therapeutic modality with the potential to treat and even cure a diverse array of diseases. Cell therapies offer unique clinical and therapeutic advantages over conventional small molecules and the growing number of biologics. Particularly, living cells can simultaneously and dynamically perform complex biological functions in ways that conventional drugs cannot; cell therapies have expanded the spectrum of available therapeutic options to include key cellular functions and processes. As such, cell therapies are currently one of the most investigated therapeutic modalities in both preclinical and clinical settings, with many products having been approved and many more under active clinical investigation. Here, we highlight the diversity and key advantages of cell therapies and discuss their current clinical advances. In particular, we review 28 globally approved cell therapy products and their clinical use. We also analyze >1700 current active clinical trials of cell therapies, with an emphasis on discussing their therapeutic applications. Finally, we critically discuss the major biological, manufacturing, and regulatory challenges associated with the clinical translation of cell therapies.

KEYWORDS
blood cell, cell, cell therapy, clinical translation, clinical trials, microbes, stem cell, T cell

1 | INTRODUCTION

Cell therapies represent a major frontier and paradigm shift in biotechnology. In contrast to conventional therapeutic modalities, cell therapies are living and can dynamically respond to biological cues to attack malignancies, regenerate tissues, restore impaired or lost biological functions, or otherwise augment the body’s own capability to fight disease (e.g., vaccination, immunomodulation).1 Cell therapies hold exceptional promise particularly because cells can function in ways that conventional small molecules and biologics cannot. Uniquely, living cells can simultaneously respond to both systemic and local chemical, physical, and biological cues, readily breach biological barriers, molecularly target and interact with specific cell types and tissues,2 and serve as a platform for additional therapeutic functions (e.g., cellular hitchhiking, genetic engineering).3,5 In this review, we have identified 28 cell therapy products approved for clinical use and...
1705 active clinical trials employing cells for therapeutic purposes. We provide a snapshot of the clinical landscape of cell therapies by: (i) highlighting these approved products; (ii) summarizing and reviewing these current clinical trials based on their cell type, indication, source, and phase; and (iii) discussing the challenges associated with clinical translation. For mammalian cell-based therapies, we restricted our analysis to applications where cells are administered as a single cell-suspension (i.e., exclusion of tissue scaffolds and whole blood transplants). Our discussion is mainly focused on blood cells (T cells, natural killer [NK] cells, red blood cells [RBCs], dendritic cells [DCs], mononuclear cells, and platelets) and stem cells. We also provide an update on the clinical status of microbe therapeutics, which have recently emerged as a promising class of cell therapies for the treatment of infections and cancer.

2 | CLINICAL LANDSCAPE

The global market for cell therapy is predominantly shared by stem cells and tissue-specific cells (e.g., skin cells, chondrocytes), followed by blood cells.6-8 Current approved stem-cell therapies include hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), and to a lesser extent limbal stem cells (LSCs). HSC products are predominantly approved for the treatment of blood disorders. MSC therapies are indicated for a broad variety of diseases, including cardiovascular diseases, graft versus host diseases (GVHD), degenerative disorders, and inflammatory bowel diseases. The single LSC product is approved for LSC deficiency. Distinct from stem cell products, terminally differentiated tissue-specific cells are mainly used for regenerative medicine and tissue engineering applications, such as autologous skin cells (i.e., keratinocytes, fibroblasts, and melanocytes) for the treatment of thermal burns,9 bi-layers of living cellular skin substitute for venous leg ulcers and diabetic foot ulcers,10 and autologous chondrocyte scaffolds for repair of cartilage defects.11 These tissue-specific cell therapies are beyond the scope of this review because they are mostly applied as tissue scaffolds instead of as single-cell suspension and have been extensively reviewed elsewhere.12-14 The third group of cell therapies consist of blood cells, including leukocytes, RBCs, and platelets; however, only T cells and DCs have been approved as therapeutic products in the market to date. Most approved T cell products are chimeric antigen receptor (CAR)-T therapies for hematologic malignancies, whereas DC products are used as vaccines for solid cancers. We should also note that RBCs and platelets, while not associated with a specific product, are widely used in clinical settings for blood transfusions.15 In addition, the cell source of these approved products can be either from the patients themselves (autologous) or from the other donors (allogeneic).

Although stem cells and tissue-specific cells account for the vast majority of approved cell therapies in the current market, blood cells have emerged as the dominant cell type that is being developed and evaluated in clinical trials. Just 5 years ago, the number of trials for MSCs alone was greater than the number of trials for all lymphocytes and DCs combined.14 Currently, T-cell trials individually outnumber all stem cell trials, and far exceed those for tissue-specific cells. This ongoing shift is driven primarily by the recent clinical success of CAR-T therapy, which is in turn a product of major breakthroughs in our understanding of how immune modulatory approaches can be used to treat disease.16-19 In light of this trend, we collected and analyzed clinical trials that use blood cells, with additional focus on stem cells delivered as single-cell suspensions, and microbes (including non-single-cell suspension dosage forms), which have recently emerged as promising agents for the treatment of infections and cancer. Specifically, we identified the trials on clinicaltrials.gov by searching for each cell type (Figure 1) with the following key words (listed in parentheses) in the “Intervention/treatment” category: T cells (“T cell”; system also automatically searched for “T lymphocyte”), stem cells (“stem cell”; system also automatically searched for “progenitor cell”), natural killer cells (“natural killer,” “NK”), dendritic cells (“dendritic cell,” “DC”; system also automatically searched for “antigen presenting cell” and “cellular”), monocytes (“monocyte”; system also automatically searched for “monocytic”), macrophages (“macrophage”), bone marrow-derived mononuclear cells (“bone marrow-derived mononuclear cell”), peripheral blood mononuclear cells (“peripheral blood mononuclear cell”; system also automatically searched for “peripheral blood,” “blood,” “whole blood”), red blood cells (“red blood cell”; system also automatically searched for “erythrocytes,” “red cells,” “whole blood,” “RBC count,” and “blood corpuscles”), platelets (“platelet”; system also automatically searched for “thrombocyte”), and microbes (“live biotherapeutic,” “bacteria,” “consortia”). In the “Status” category under “Recruitment,” we selected trials with statuses of not yet recruiting, recruiting, enrolling by invitation, and active/not recruiting. The collected data capture the clinical landscape as of August 2020. We then manually filtered the trials to exclude entries that mentioned the cell types of interest but did not use them as therapeutic interventions. Finally, we excluded long-term follow-up studies that did not involve re-administration of the therapy. A list of abbreviations used through this manuscript is shown in Table S1.

FIGURE 1 Various types of cell therapies in clinical trials. T cells dominate the current clinical studies of cell therapies, followed by stem cells, dendritic cells, natural killer cells, microbes, red blood cells, mononuclear cells, and platelets

WANG ET AL.
A total of 1705 unique, active cell therapy clinical trials have been identified and categorized according to cell type, general indication, trial phase, and cell source (Figure 2). Among only leukocytes, T cells account for the largest portion of all current trials (767/1705, 45%), followed by DCs (136/1705, 8%), NK cells (116/1705, 7%), and the remaining mononuclear cells (27/1705, 2%). It is unsurprising that the main indication of T cells, DCs, and NK cells is cancer (85% in T cells; 93% in DCs; 95% in NK cells), as they play major roles in anti-cancer immunity. T cells are adaptive immune cells capable of directly eliminating mutated or infected host cells, activating other immune cells, and producing cytokines to regulate immune responses. NK cells are innate immune cells that destroy tumor cells and virally infected cells via release of lytic molecules from granules and rapid production of pro-inflammatory cytokines. DCs are professional antigen-presenting cells (APCs) that regulate adaptive immune cells by delivering antigens to draining lymph nodes and presenting them to cytotoxic and helper T cells. In the case of cancer treatment, T and NK cells are employed as cytotoxic agents, while DCs primarily serve as cancer vaccines. From the perspective of cell source, autologous cells are mainly used in T cell (74%) and DC (87%) therapy, as allogeneic cells increase the risk of allograft rejection (recipient cells against donor cells) or, more consider-ably, GvHD (donor cells against recipient cells).

**FIGURE 2** Current landscape of cell therapies in clinical trials. In this review, all clinical trials that include blood cells and stem cells delivered as a suspension were cataloged. Trials using microbes (delivered via various routes and dosage forms) were also included, as they represent an emerging class of therapies for similar applications. The relevant cell types include T cells, NK cells, mononuclear cells, DCs, RBCs, platelets, stem cells, and microbes. Tissue-specific cells were excluded from the analysis. The total number of trials identified for each cell type is displayed in the figure, however the sum of these trials for all cell types (1760) exceeds the total number of analyzed trials (1705) because some trials use two or more cell therapies in combination. For phase classification, dual-phase trials (e.g., Phase 1/2) were counted as both Phase 1 and 2. Eleven broad indications were identified for the purpose of trial classification (i.e., cancer, infectious diseases, autoimmune diseases, nonautoimmune inflammatory diseases, cardiovascular diseases, transplant-related diseases, trauma, blood disorders, degenerative diseases, metabolic disorders, etc.), with relevant abbreviations listed in the box at the bottom of the figure. Because some trials are used to treat more than one of these conditions, the total number of indications used to generate each pie chart exceeds the total number of trials for each cell type.
While the aforementioned leukocytes are mainly indicated for the treatment of cancer, the remaining mononuclear cells are used mostly for cardiovascular diseases (39%) and cancer (29%). For the purpose of this review, we refer to mononuclear cells as belonging to one of the following cell populations: monocytes, macrophages, bone marrow-derived mononuclear cells (BMMCs), or peripheral blood mononuclear cells (PBMCs). Monocytes are circulatory cells of the innate immune system that extravasate into tissue in response to inflammation, infection, or injury. Once in the tissue they terminally differentiate into macrophages, which are tissue-resident innate immune cells that (i) phagocytose dead cells, debris, and foreign materials/pathogens, (ii) modulate innate immune responses, and (iii) maintain homeostatic growth, repair, and metabolism. BMMCs are a heterogeneous group of cells composed of lymphoid cells, myeloid cells, HSCs, and MSCs. They have major clinical applications in cardiovascular tissue regeneration due to their ability to differentiate into various lineages. Similar to BMMCs, PBMCs also contain a variety of cells including lymphocytes, monocytes, and a small percentage of DCs and are mainly indicated for cancers. Currently, there are no Phase 4 trials employing mononuclear cells, with similar representations across Phases 1–3. In addition, autologous mononuclear cells are employed almost exclusively (89%), likely to reduce the risk of graft rejection and GvHD.

The remaining blood cells, RBCs and platelets, are used as cell therapies for treatment of blood disorders and in trauma care via blood transfusions, and account for 2% (39/1705) and <0.4% (7/1705) of all current cell therapy trials, respectively (Figure 2). Typically, they are used to replenish lost or dysfunctional cells to maintain homeostasis in the body. The RBC is a critical transporter of oxygen and nutrients to tissues as well as an inter-organ communicator, with additional roles in the regulation of pH, redox homeostasis, and molecular metabolism. Hence, loss of RBC integrity and/or number can lead to severe pathologies and heighten the incidence of vascular disease. Similarly, the platelet serves as a key element in blood vessels by regulating hemostasis under normal conditions and thrombosis upon vascular damage. Thrombocytopenia (i.e., platelet deficiency) that results from either trauma or blood disorders can lead to hemorrhage in tissues or uncontrolled bleeding of wounds. Both RBC and platelet therapy largely apply allogeneic cells (77% and 86%, respectively) in clinical settings. Still, the use of allogeneic RBCs requires blood type matching between donor and recipient. The major efforts in current RBC and platelet clinical trials are focused on optimizing transfusion protocols and verifying the durability of transfused cells.

Other than blood cells, stem cells account for 36% of current cell therapy trials (620/1705) as the second largest cell category of focus for this review. The trials of stem cell therapy, primarily those of HSCs and MSCs, encompass a wide range of indications covering 10 broad disease classifications (Figure 2). HSCs are multipotent stem cells capable of self-renewing and differentiating into mature blood cells that form the myeloid and lymphoid cell lineages. As a result, hematopoietic stem cell transplantation (HSCT) can be used to reconstitute the hematopoietic and immunologic systems for the treatment of inherited and acquired blood disorders. HSCT is also used frequently to treat blood cancers after cancerous cells are eliminated by a myeloablative treatment. While autologous HSCs or matched sibling donor HSCs are the most ideal candidates for HSCT due to the reduced risk of GvHD, graft rejection, and engraftment syndrome, allogeneic HSCs have an advantage in cancer treatment because they can elicit graft-versus-tumor effects. MSCs, also a type of multipotent stem cell, are capable of effectively differentiating into a wide variety of cell types in mesodermal (e.g., chondrocytes), ectodermal (e.g., neurocytes), and endodermal lineages (e.g., hepatocytes).

As a result, they have broad applications in clinical settings for the treatment of degenerative diseases, autoimmune diseases, inflammatory diseases, and trauma, among others. Notably, most stem cell therapy trials are in early stages with nearly equal representation in Phase 1 (44%) and Phase 2 (47%), showing their considerable potential to affect the future scope of cell therapies. Finally, microbes comprise 3% of the total trials (48/1705) with major indications including cancer (44%), infectious diseases (19%), and inflammatory diseases (13%). Although metabolic disorders account for only 8% of the indications for microbes, it is worth mentioning this unique niche, as very few cell therapies are investigated for this indication. Microbes exert therapeutic mechanisms of action by (i) displacing pathogenic microbiomes to restore symbiosis and (ii) producing therapeutic biomolecules, a function enabled by genetic modification.

### 3 | CLINICALLY APPROVED PRODUCTS

In the following sub-sections, we provide additional details on approved cell therapy products that presently include T cells, stem cells, and DCs (Table 1). We also discuss closely related modalities, namely the applications of donor blood products and microbe-based therapies in the clinic. Of note, many of these approved cell therapies are being developed and evaluated in current trials for additional indications, as summarized in Table S2.

#### 3.1 | T cells

A total of four T-cell products have been approved globally as of 2020, three by the FDA (USA) and one by the Korea Food & Drug Administration (KFDA) (Table 1). All FDA-approved T-cell products are for CAR-T therapy, which is a form of immunotherapy that uses T cells genetically modified with a CAR to recognize and destroy cancer cells. The two essential components of a CAR include (i) an extracellular target binding domain used to identify surface antigens on cancer cells and (ii) an intracellular signaling portion comprised of costimulatory and activation domains that initiate processes including activation, clonal expansion, and cell killing. New functional domains are now being explored in both preclinical and clinical settings with the aim of providing safer and more effective CAR-T therapies. Of note, all approved CAR-T products are autologous and contain CARs targeting CD19, a biomarker that is selectively expressed on the surface of B cells. Accordingly,
| Name [Trade Name] (Manufacturer) | Cell source | Approved indications | Approval year | Notes |
|-----------------------------------|-------------|----------------------|---------------|-------|
| T cell                            | Autologous  | Relapsed or refractory (r/r) B-cell precursor acute lymphoblastic leukemia (ALL); r/r large B-cell lymphoma after two or more lines of systemic therapy including 1) diffuse large B-cell lymphoma (DLBCL) not otherwise specified, 2) high-grade B-cell lymphoma, and 3) DLBCL arising from follicular lymphoma | 2017 (USFDA), 2018 (EMA), 2018 (Health Canada), 2019 (JMHW), Australia, Israel, Switzerland | GM; CAR/CD19 (receptor/target) |
| Tisagenlecleucel [Kymriah®] (Novartis) | Autologous  | Relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including 1) diffuse large B-cell lymphoma (DLBCL) not otherwise specified, 2) primary mediastinal large B-cell lymphoma, 3) high-grade B-cell lymphoma, and 4) DLBCL arising from follicular lymphoma | 2017 (USFDA), 2018 (EMA), 2019 (Health Canada) | GM; CAR/CD19 (receptor/target) |
| Axicabtagene ciloleucel [Yescarta®] (Kite) | Autologous  | Relapsed or refractory mantle cell lymphoma | 2020 (USFDA) | GM; CAR/CD19 (receptor/target) |
| Brexucabtagene autoleucel [Tecartus™] (Kite) | Autologous  | Hepatocellular carcinoma, brain tumors, and pancreatic cancer | 2007 (KFDA), 2018 (as Orphan Drug Designation by USFDA) | NGM; TAA (target) |
| N/A [ImmunCell-LC®] (Green Cross Cell) | Autologous  | Disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment | 2011 (USFDA) | NGM |
| HPC, Cord Blood [Allocord] (SSM Cardinal Glennon Children's Medical Center) | Allogeneic  | Disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment | 2011 (USFDA) | NGM |
| HPC, Cord Blood [Clevecord™] (Cleveland Cord Blood Center) | Allogeneic  | Disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment | 2016 (USFDA) | NGM |
| HPC, Cord Blood [Ducord™] (Duke University School of Medicine) | Allogeneic  | Disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment | 2012 (USFDA) | NGM |
| HPC, Cord Blood [Hemacord™] (New York Blood Center) | Allogeneic  | Disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment | 2011 (USFDA) | NGM |
| HPC, Cord Blood [N/A] (Clinimmune Labs, University of Colorado Cord Blood Bank) | Allogeneic  | Disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment | 2012 (USFDA) | NGM |
| HPC, Cord Blood [N/A] (MD Anderson Cord Blood Bank) | Allogeneic  | Disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment | 2018 (USFDA) | NGM |
| HPC, Cord Blood [N/A] (LifeSouth Community Blood Centers) | Allogeneic  | Disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment | 2013 (USFDA) | NGM |
| HPC, Cord Blood [N/A] (Bloodworks) | Allogeneic  | Disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment | 2016 (USFDA) | NGM |
| Betibeglogene autotemcel [Zynteglo™] (bluebird bio) | Autologous  | Transfusion-dependent thalassemia | 2019 (EMA) | GM |

(Continues)
| Name [Trade Name] (Manufacturer) | Cell source | Approved indications | Approval year | Notes |
|---------------------------------|-------------|----------------------|---------------|-------|
| N/A [Strimvelis®] (GlaxoSmithKline) | Autologous | Adenosine deaminase-severe combined immunodeficiency (ADA-SCID) | 2016 (EMA) | GM |
| N/A [Cellgram™] (Pharmicell) | Autologous | Acute myocardial infarction | 2011 (KFDA) | NGM; BM-MSC (cell subtype) |
| N/A [Cartistem®] (Medipost) | Allogeneic | Repetitive and/or traumatic cartilage degeneration, including degenerative osteoarthritis without age limit | 2012 (KFDA) | NGM |
| N/A [Queencell®] (Anterogen) | Autologous | Subcutaneous tissue defects | 2010 (KFDA) | NGM; adipose-derived MSC (cell subtype) |
| Darvadstrocel [Alofisel®] (TiGenix NV/Takeda) | Allogeneic | Complex perianal fistulas in Crohn’s disease | 2018 (EMA) | NGM; adipose-derived MSC (cell subtype) |
| N/A [Cupistem®] (Anterogen) | Autologous | Crohn’s fistula | 2012 (KFDA) | NGM; adipose-derived MSC (cell subtype) |
| Remestemcel-L [Prochymal®] (Osiris Therapeutics/ Mesoblast Limited) | Allogeneic | Steroid-refractory acute GvHD (pediatric) | 2012 (Health Canada) | NGM; BM-MSC (cell subtype) |
| N/A [TEMCELL® HS Inj.] (JCR Pharmaceutics) | Allogeneic | Acute GvHD following hematopoietic stem cell transplant | 2015 (Japan) | NGM; BM-MSC (cell subtype) |
| Lenzumestrocel [NeuroNata-R®] (Corestem) | Autologous | Amyotrophic lateral sclerosis | 2014 (KFDA) | NGM |
| N/A [Stemirac] (Unique Access Medical) | Autologous | Spinal cord injury | 2018 (JMHW, conditional approval) | NGM |
| N/A [Stempeucel®] (Stempeutics) | Allogeneic | Critical limb ischemia due to Buerger’s disease | 2017 (DCGI, limited marketing approval) | NGM |
| N/A [Holoclair®] (Chiesi) | Autologous | Limbal stem cell deficiency | 2015 (European Commission) | NGM |
| Dendritic cell | Autologous | Asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer | 2010 (USFDA), 2013 (EMA) | NGM |
| N/A [CreaVax-RCC®] (JW CreaGene) | Autologous | Metastatic renal cell carcinoma (post-nephrectomy) | 2007 (KFDA) | NGM |
| N/A [APCeden®] (APAC Biotech) | Autologous | Prostate cancer, ovarian cancer, colorectal cancer, non-small cell lung carcinoma | 2017 (CDSCO) | NGM |

**Abbreviations:** Indications: GvHD, Graft versus host disease. Agencies: CDSCO, Central Drugs Standard Control Organization (CDSCO), aka Indian FDA; EMA, European Medicines Agency; DCGI, Drug Controller General of India; KFDA, Korea Food and Drug Administration; JMHW, Japanese Ministry of Health and Welfare; USFDA, The United States Food and Drug Administration. Notes: BM, bone marrow; CAR, chimeric antigen receptor; GM, genetically modified; NGM, nongenetically modified; TAA, tumor-associated antigen.
CAR-T cells are indicated for relapsed or refractory (r/r) B-cell malignancies.

Kymriah®, approved by the FDA in 2017, was the first T-cell therapy available in the United States. Kymriah® is indicated for the treatment of children and young adults with r/r B-cell precursor acute lymphoblastic leukemia (r/r B cell ALL) and adult patients with certain types of r/r large B-cell lymphoma after the failure of at least two lines of systemic therapy. Yescarta® also received FDA approval in 2017 for the treatment of certain types of r/r large B-cell lymphoma in adult patients who resist two or more lines of systemic therapy. Both Kymriah® and Yescarta® are being investigated in current clinical trials for additional liquid cancers (Table S2). Notable differences between Kymriah® and Yescarta® include their costimulatory domains (4-1BB vs. CD28) and the associated persistence of the infused CAR-T cells (1–7 years vs. <6 weeks). In 2020, a third CAR-T product, Tecartus™, received approval from the FDA to treat adults with r/r mantle cell lymphoma (MCL), which is an aggressive, rare form of non-Hodgkin lymphoma. Unlike the two previously approved CAR-T therapies, the Tecartus™ manufacturing process incorporates an additional step to enrich the T-cell population and remove circulating tumor cells (CTCs) from patients’ leukapheresis material. This process prevents CAR-T cell activation and subsequent exhaustion during ex vivo manufacturing.

Although CAR-T products are indicated solely for hematological malignancies, other T cells have been used to treat solid tumors. ImmunCell-LC®, an autologous cytokine-induced killer (CIK) cell-based immunotherapy, was approved by the KFDA in 2007 and earned orphan drug designation from the FDA in 2018. It is employed as an adjuvant therapy after tumor resection, and has been used for the treatment of hepatocellular carcinoma, brain tumors, and pancreatic cancer by eliminating residual tumor cells. ImmunCell-LC® is manufactured by isolating PBMCs and incubating them with interleukin-2 (IL-2) and anti-CD3 antibody, to collect activated T lymphocytes. ImmunCell-LC® showed an increased rate of recurrence-free and overall survival in patients who underwent tumor resection. Additional clinical trials of ImmunCell-LC® are underway for hepatocellular carcinoma.

3.2 | Stem cells

Our search revealed a total of 21 stem cell products that have been approved globally, with 12 approved by the FDA (USA) or European Medicines Agency (EMA, Europe). The remaining nine products are approved in other countries, particularly in Asia (Table 1). Notably, all but one product are composed of HSCs or MSCs.

3.2.1 | Hematopoietic stem cells

There are 10 approved HSC products globally, with eight approved by the FDA and the remaining two by the EMA (Table 1). The FDA approved the first batch of products, Allocord and Hemacord™, in 2011. Subsequently, six more similar products were FDA approved, with the most recent in 2018. All of these products are cord blood-based therapies that have applications for malignant and non-malignant blood disorders and immunodeficiency disorders. Notably, cord blood-based HSCs offer considerable advantages over other forms of allogeneic HSCT, such as easier accessibility, higher tolerance for human leukocyte antigen (HLA) mismatch, and a lower risk of GVHD. While pediatric HSCT is still exclusively performed with HLA-matched cord blood from a sibling, the tolerance for 1-2 HLA-A, -B, and -DR mismatches has loosened to enable the considerable expansion of the HSCT-eligible adult patient population.

In addition, Strimvelis® and Zynteglo™ are autologous HSC-based gene therapies that have been EMA approved. Strimvelis®, EMA approved in 2016, is indicated for adenosine deaminase deficiency (ADA-SCID), an immunodeficiency disorder caused by mutations in the gene coding for adenosine deaminase (ADA). Zynteglo™, EMA approved in 2019, is employed for transfusion-dependent thalassemia, a genetic disorder caused by mutations in the β-globin gene that result in considerably reduced or absent adult hemoglobin. Zynteglo™ uses the lentiviral vector Lentiglobin BB305 to transduce autologous CD34+ cells with the β-globin gene. These cells are then infused back to the patient and traffic to the bone marrow, where they differentiate into mature RBCs with functional hemoglobin. Several current clinical trials are exploring the use of Lentiglobin BB305 for applications including thalassemia and sickle cell disease.

3.2.2 | Mesenchymal stem cells

There are 10 MSC products that have been approved globally as of 2020 (Table 1), although none have been approved by the FDA. The current MSC products fall into two major categories according to their mechanisms of action and approved indications: (i) tissue repair and (ii) immunomodulation.

MSCs have multipotent potential and can differentiate into a variety of cell types, such as osteoblasts, chondrocytes, myocytes, adipocytes, and neuronal cells. Based on this biological function, three MSC therapies have been approved for tissue repair applications (Table 1). Cellgram™, an autologous MSC therapy, was approved by the KFDA in 2011 for acute myocardial infarction. Mechanisms of action of Cellgram™ are reported to involve (i) MSCs’ capability to differentiate into cardiac myocytes and (ii) MSCs’ pleiotropic secretomes that promote angiogenesis. Another MSC-based tissue repair product, Cartistem®, was approved by the KFDA in 2012 for repetitive and/or traumatic cartilage degeneration, including degenerative osteoarthritis. Queencell®, an autologous adipose-derived cell product, was also approved by the KFDA, in 2010, for the treatment of subcuteaneous tissue defects. However, unlike other approved MSCs, Queencell® is not composed of pure MSCs and is instead comprised of a mixture of MSCs, pericytes, mast cells, fibroblasts, and endothelial progenitor cells.

MSCs also have immunomodulatory capabilities that can be used to regulate immune responses in many pathologies. Based on this
MSC products, Holoclar®, an autologous LSC product, won EMA osteochondral lesions (Table S2). In addition to the approved HSC and syndrome (ARDS) due to coronavirus disease 2019 (COVID-19), and indications including alcoholic liver cirrhosis, acute respiratory distress.

To produce Provenge®, the resistant prostate cancer. Of note, it is the first cell therapy used as approvals by the FDA, KFDA, and Indian FDA (Table 1). Provenge® There are currently three DC products in the global market with 8o f3 6 capability, seven MSC products have been approved for indications including Crohn's fistula (Alofisel®, Cupistem®, acute GvHD (aGvHD) (Prochymal®, TEMCELL®), amyotrophic lateral sclerosis (ALS) (NeuroNata-R®), spinal cord injury (Stemirac), and critical limb ischemia due to Buerger's disease (Stempecel®) (Table 1). Alofisel®, an allogeneic MSC therapy for complex perianal fistula in Crohn's disease, is the only MSC product approved by the EMA. Its mechanism of action seems to involve MSCs' ability to inhibit the proliferation of activated lymphocytes and thereby reduce pro-inflammatory cytokine production. A similar product, Cupistem®, is an autologous adipose-derived MSC product that received approval from the Canadian Food Inspection Agency (CFIA) for the treatment of steroid-refractory acute GvHD (SR-aGvHD) in pediatric patients. Of note, Prochymal® received approval from the FDA, CreaVax®, an autologous DC therapy, was approved by the Indian FDA in 2017 for the treatment of prostate, ovarian, colorectal, and non-small cell lung cancers.

3.3 | Dendritic cells

There are currently three DC products in the global market with approvals by the FDA, KFDA, and Indian FDA (Table 1). Provenge® won FDA approval in 2010 for the treatment of metastatic castrate-resistant prostate cancer. Of note, it is the first cell therapy used as a cancer vaccine in the United States. To produce Provenge®, the patient's leukocytes are collected and then expanded ex vivo with a prostate cancer tissue antigen (prostatic acid phosphatase [PAP]) and granulocyte-macrophage colony-stimulating factor (GM-CSF). This autologous multicell suspension composed primarily of DCs, but also other leukocytes, is administered intravenously in three doses, each separated by 2 weeks. The main mechanism of action is the DC-mediated presentation of PAP to the patient's T cells, which elicits an adaptive immune response against the prostate cancer cells. While Provenge® is the only DC therapy approved by the FDA, CreaVax®, an autologous DC therapy, was approved by the KFDA in 2007 for renal cell carcinoma. Similarly, APCedent® is an autologous DC therapy approved by the Indian FDA in 2017 for the treatment of prostate, ovarian, colorectal, and non-small cell lung cancers.

3.4 | Other cell-based therapies (transfusions, transplants, and supplements)

While donor blood products have a long history in the treatment of some blood disorders and deficiencies, there are no specific approved products for RBCs and platelets. RBCs are administered to patients who are anemic due to a blood disorder (i.e., thalassemia, sickle cell disease, iron or other vitamin deficiency, aplastic anemia), or as a result of trauma or injury. Prior to intravenous administration, blood must be ABO blood type and Rhesus D (RhD) matched. Packed RBC infusions are given most commonly, although whole blood can also be administered. In many cases, autologous blood is isolated prior to a surgical procedure in anticipation of potential blood loss. Currently, drugs cannot be mixed with donor blood prior to infusion. Platelet transfusions are indicated for the treatment of thrombocytopenia, which can occur as a result of disease or in response to cancer treatment. Current clinical studies continue to investigate the range of suitable storage conditions and dosing regimens for donor platelets.

To the best of our knowledge, there are no microbe-based therapies that have been approved for clinical use by the FDA or EMA. However, there are two closely related modalities currently used in the clinic. The first are fecal microbiota transplants (FMTs), in which a solution of fecal matter from a healthy donor is supplied to the intestinal tract of the patient to alter the gut microbiome composition. While these transplants are used to treat a variety of diseases in clinical settings, they are beyond the scope of this review because they are not being developed as individual drug products. The second type of therapy, probiotics, includes living microorganisms that are widely available over the counter and can also be prescribed by clinicians. However, they are also beyond the scope of this review because they are typically categorized as foods, functional foods, or supplements, and as such do not undergo the same regulatory process as pharmaceuticals.

4 | CURRENT CLINICAL TRIALS

In the following sub-sections, we categorize and discuss current clinical trials employing blood cells and stem cells administered as single-cell suspensions, and on microbes administered in various dosage forms. We define current clinical trials as those that appear on clinicaltrials.gov with a status of not yet recruiting, recruiting, enrolling by invitation, or active/not recruiting. These sub-sections account for data that capture the current clinical landscape as of August 2020. The overall summary of our analysis and additional details are shown in Figure 2.

4.1 | T cells

The clinical landscape of T-cell therapies has rapidly diversified over the past 10 years. Today, T cells are the most investigated cell type among all cell therapy trials, encompassing 45% of the total trials (Figure 2). A representative selection of T-cell trials is shown in Table 2. In our analysis, we grouped 767 T-cell trials into four main
| Cell type | GM | Receptor type | Target | Source | Indication | Name (Sponsor) | Route | Payload | Trial number | Other trials and/or notes |
|-----------|----|---------------|--------|--------|------------|---------------|-------|---------|--------------|--------------------------|
| T cell    | No | TAA           | NY-ESO-1, MAGE-A4, PRAME, survivin, and/or SSX | Autologous | Lymphoma | N/A (Baylor College of Medicine) | IV    | N/A    | NCT01333046 (Phase 1) | NCT03192462 (Phase 1/2), NCT02239681 (Phase 1), NCT03093350 (Phase 2) |
| T cell    | No | Virus specific EBV | Autologous | Nasopharyngeal carcinoma | N/A (Tessa Therapeutics) | IV    | N/A    | NCT02578641 (Phase 3) | None |
| T cell    | Yes | CAR | CEA | Autologous | Liver metastasis | Anti-CEA CAR-T (Sorrento Therapeutics) | Hepatic artery N/A | NCT040002741 (Phase 2/3) | NCT03818165 (Phase 1), NCT02850536 (Phase 1), NCT03682744 (Phase 1) |
| T cell    | Yes | CAR | CD19, CD20 | Autologous | Leukemia, lymphoma | CD20-CD19 cCAR (iCell Gene Therapeutics) | IV    | N/A    | NCT04156178 (Phase 1) | Dual CAR-T |
| T cell    | Yes | CAR | BCMA | Autologous | Multiple myeloma | bb2121 (Celgene) | IV    | N/A    | NCT03651128 (Phase 3) | NCT03361748 (Phase 2), NCT03601078 (Phase 2), NCT02658929 (Phase 1), NCT04196491 (Phase 1) |
| T cell    | Yes | CAR | CD19 | Allogeneic | Lymphoma | CTX 110 (CRISPR Therapeutics) | IV    | N/A    | NCT04035434 (Phase 1/2) | CRISPR/Cas9 edited |
| T cell    | Yes | TCR | MAGE-A10 | Autologous | Urothelial carcinoma | MAGE-A10c796T (Adaptimmune) | IV    | N/A    | NCT02989064 (Phase 1) | NCT02592577 (Phase 1) |
| T cell    | Yes | TCR | HPV | Autologous | Oropharyngeal cancer | E7 TCR T (National Cancer Institute) | IT    | N/A    | NCT04044950 (Phase 2) | NCT04476251 (Early Phase 1), NCT02858310 (Phase 1/2), NCT04015336 (Phase 2) |
| T cell    | Yes | CAR | CD19 | Autologous | Leukemia, lymphoma | N/A (Uppsala University) | IV    | N/A    | NCT03068416 (Phase 2) | Third-generation CAR |
| T cell    | Yes | CAR | GPC3 | Autologous | Solid tumors | AGAR T Cells (Baylor College of Medicine) | iCas9 suicide gene, IL-15 secretion | NCT04377932 (Phase 1) | None |
| T cell    | Yes | TCR | HA-1 | Allogeneic | Leukemia | N/A (Fred Hutchinson Cancer Center) | IV    | Suicide gene | NCT03326921 (Phase 1) | None |
| T cell (TIL) | No | N/A | N/A | Autologous | Renal cell carcinoma | Nivo-TIL (Nantes University Hospital, Bristol Meyers Squibb) | IV    | N/A    | NCT03374839 (Phase 1) | None |
| T cell | No | TAA | WT1 | Allogeneic | Leukemia | WT1-CTL (Atara Biotherapeutics) | IV    | N/A    | NCT0620633 (Phase 1) | None |

(Continues)
| Cell type | GM | Receptor type | Target | Source | Indication | Name (Sponsor) | Route | Payload | Trial number | Other trials and/or notes |
|-----------|----|---------------|--------|--------|------------|---------------|-------|---------|-------------|--------------------------|
| T cell    | Yes| CAR           | IL13Ra2| Autologous | Glioblastoma | N/A (City of Hope Medical Center) | IT, IC, IVN | CD19t suicide gene | NCT02020362 (Phase 1) | NCT04310051 (Phase 1), NCT04003649 (Phase 1) |
| T cell    | Yes| TCR           | CD19   | Autologous | Lymphoma     | ET1901 ARTEMIS™ (Eureka Therapeutics) | IV    | N/A     | NCT03415399 (Phase 1) | Novel TCR |
| Transplant-related diseases (n = 63) | | | | | | | | | |
| T cell    | No | Virus-specific | CMV, EBV, ADV | Allogeneic | Viral infection | N/A (University of Pittsburgh) | IV    | N/A     | NCT043614178 (Phase 1/2) | None |
| T cell (Treg) | No | N/A | N/A | Allogeneic | GvHD | TREG2015001 (European Commission) | IV    | N/A     | NCT02749084 (Phase 1/2) | None |
| T cell    | No | TCR           | EBV    | Allogeneic | EBV-associated post-transplant lymphoproliferative disease | Tabelecleucel (Atara Biotherapeutics) | IV    | N/A     | NCT03392142 (Phase 3) | NCT03769467 (Phase 1/2), NCT0394365 (Phase 3) |
| Infectious diseases (n = 24) | | | | | | | | | |
| T cell    | No | Virus-specific | HIV    | Autologous | Viral infection | HXTC (University of North Carolina, Chapel Hill) | IV    | N/A     | NCT03212989 (Phase 1) | None |
| T cell    | Yes| CAR           | HIV    | Autologous | Viral infection | N/A (Guangzhou 8th People's Hospital) | IV    | N/A     | NCT03240328 (Phase 1) | NCT03980691 (Phase 1) |
| T cell    | No | Virus-specific | SARS-CoV-2 | Allogeneic | Viral infection | N/A (Children's Hospital Medical Center, Cincinnati) | IV    | N/A     | NCT04406064 (Phase 1) | None |
| Autoimmune diseases (n = 12) | | | | | Type I diabetes | N/A (Second Xiangya Hospital of Central South University) | IV    | N/A     | NCT031011021 (Phase 1/2) | NCT02932826 (Phase 1/2) |
| T cell (Treg) | No | N/A | N/A | Allogeneic | Crohn’s disease | TR004 (King's College London) | IV    | N/A     | NCT03185000 (Phase 1/2) | None |
| Non-autoimmune inflammatory diseases (n = 3) | | | | | | | | | |
| T cell (Treg) | No | N/A | N/A | Allogeneic | Crohn’s disease | TR004 (King's College London) | IV    | N/A     | NCT03185000 (Phase 1/2) | None |
| Other (n = 19) | | | | | | | | | |
| T cell    | Yes| CAR           | BCMA   | Autologous | Myasthenia gravis | Descartes-08 (Cartesian Therapeutics) | IV    | N/A     | NCT04146051 (Phase 1/2) | NCT03448978 (Phase 1/2) |
| T cell (Treg, Th2) | No | N/A | N/A | Autologous | Amyotrophic lateral sclerosis | RAPA-501 (Rapa Therapeutics) | IV    | N/A     | NCT04220190 (Phase 1/2) | None |

Abbreviations: Cell Subtypes: CAR, chimeric antigen receptor; TAA, tumor-associated antigen; TCR, T-cell receptor; TIL, tumor-infiltrating lymphocyte; Treg, regulatory T cell; Th2, T helper cell type 2. Targets: ADA, adenosine deaminase; ADV, adenovirus; BCMA, B-cell maturation antigen; Bcl11a, B-cell leukemia/lymphoma 11a; CMV, cytomegalovirus; CD, cluster of differentiation; CEA, carcinoembryonic antigen; CCR5, C-C chemokine receptor type 5; EBV, Epstein Barr virus; GPC3, glypican 3; HER2, human epidermal growth factor receptor 2; HA-1, minor histocompatibility antigen; HPV, human papillomavirus; HIV, human immunodeficiency virus; IL13Ra2, IL-13 receptor alpha 2; MAGE4, melanoma-associated antigen 4; MAGE-A10, melanoma-associated antigen 10; NY-ESO-1, New York esophageal squamous cell carcinoma-1; NKG2DL, natural killer group 2D ligand; PRAME, preferentially expressed antigen in melanoma; Rev, regulator of expression of virion proteins; SSX, synovial sarcoma X chromosome breakpoint; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; Tat, transactivator of expression; WT1, Wilms tumor antigen 1. Indications: GvHD, graft versus host disease. Routes: IV, intravenous; IT, intratumoral; IC, intracavitary; IVN, intraventricular. Payloads: iCas9, inducible caspase 9; CD19t, truncated CD19.
categories. We first classified them according to genetic modification status as genetically modified (GM) or nongenetically modified (NGM). Cells in the GM category were then classified according to receptor type, either CAR or T-cell receptor (TCR). Cells in the NGM category were classified according to the type of target, as these cells are usually trained ex vivo to target either tumor-associated antigens (TAA) or viral antigens (virus-specific, VST) via endogenous TCRs. Trials that could not be sorted into one of these categories were labeled “not applicable (N/A)” if there was no stated receptor or target, or “Other” if there were unique features that prevented clear classification, such as receptors that could not be readily identified as a CAR or TCR.

About 77% of the T-cell clinical trials involve GM cells; this is expected given the dominance of CAR-T therapy in the field (Figure 3). Indeed, 82% of the trials involving GM cells, or 63% of all T-cell trials, include T cells with a CAR modification (Figure 3(a)). However, this subset is highly diverse. While all three approved CAR-T therapies include a single anti-CD19 CAR for the treatment of B-cell malignancies, CD19 comprises only 37% of all targets in the clinical landscape (Table S3). The next most abundant targets include BCMA, CD22, and CD20, all of which are also exclusively found on B cells (Table S3). Together with CD19, they comprise 58% of the targets that are currently investigated in CAR-T clinical trials, reflecting the continued prevalence of B-cell cancer indications in the field. One new approach for the treatment of liquid cancers is dual CAR-T therapy, in which two different CARs are presented on the same cell or two distinct CAR-T products are co-infused. Historically, CAR-T therapy has been ineffective in the treatment of solid tumors due to a lack of defined extracellular antigen targets, insufficient T-cell infiltration, and challenges overcoming immunosuppressive tumor microenvironments. Still, about 24% of CAR-T targets in the clinical landscape are found on solid tumors (Figure 3(a)) with the most common targets being GD2 (neuroblastomas and melanomas), mesothelin (mesothelioma and cancers of the ovary, pancreas, colon, etc.), HER2 (metastatic breast cancers), and GPC3.
(liver cancers) (Table S3). Based on our analysis, intravenous administration remains the most common route of administration for CAR-T therapy against solid tumors (75%), though other administration routes are also being investigated, such as intraperitoneal, intraventricular/intracavitary, intratumoral, intra-hepatic artery, intrapancreatic (via splenic vein or artery), and intrapleural administration. The emergence of strategies to prevent T-cell exhaustion, improve target specificity, and promote tissue infiltration may expand the current application of CAR-T therapies against solid tumors (Section 5).62

The next major class of GM T cell is the TCR-T cell, which comprises about 12% of trials involving GM T cells (Figure 3(a)). While most current CARs are only capable of recognizing cell surface antigens, TCRs recognize peptides derived from intracellular proteins by binding to major histocompatibility complex (MHC) class I molecules on target cells. As a result, 81% of TCR-T trials have targets that are exclusive to solid tumors (Figure 3(a) (ii) bar and Table S4), as these cancers often do not overexpress a readily identifiable extracellular antigen that can be recognized by a CAR. Common indications include hepatocellular carcinoma, melanoma, and head and neck squamous cell carcinoma. TCR-T cells are mostly autologous (88%) (Figure 3(a) (ii)) with a small yet burgeoning group of allogeneic therapies, most of which are specific for Epstein–Barr virus (EBV). The TCR category also includes some novel, TCR-like receptors with unique properties. For example, TCRs containing an antigen-binding fragment (Fab) coupled with portions of native TCR chains can expand TCR targeting ability to extracellular antigens and has also shown reduced cytotoxicity compared to other engineered TCRs (NCT03415399).61,63

There also exists a subset of GM T cells that are not transduced with a receptor (Figure 3(a) (iii)), which, unlike CAR- and TCR-T cells, predominantly use allogeneic cells. This subset most often contains genetic modifications that enable the display of an inducible suicide gene (discussed in Section 5), expression of receptors, or secretion of therapeutic payloads like cytokines. The T-cell subtypes in this group are diverse and include regulatory T cells (Tregs), tumor-infiltrating lymphocytes (TILs), and helper T cells in addition to general peripheral populations. For example, BPX-501 is an allogeneic, suicide gene-transduced polyclonal T cell replacement product designed to prevent GVHD and improve immune reconstitution after HSCT (NCT02065869, NCT02231710). The small subset of GM cell trials classified as “Other” either contain synthetic receptors that cannot be classified as a CAR or TCR, or combinations of more than one receptor type. Many of these include CAR-T cells that also have endogenous TCRs for viral-specific targets, enabling the dual targeting of cancers induced by oncogenic viruses.

NGM T cells account for a 24% of the total T-cell trials (Figure 3 (b)), yet they have broader indications compared to GM T cells. T cells that have been primed to target specific antigen(s) via endogenously expressed TCRs can be broadly classified into viral-specific T (VST) and TAA-specific T (TAA-T) cells. VSTs are being clinically evaluated for treatment of cancer, transplant-related diseases, and infection. They can be used to eliminate virus-induced cancers by recognizing viral epitopes presented on MHC class I molecules of infected cells (NCT02578641). Another subset of VSTs are designed to treat viral infections occurring after a HSCT (NCT04364178). In this case, VSTs can be used prophylactically or following diagnosis to prevent infection-associated complications and improve transplant engraftment.64 The most common targets for this application are cytomegalovirus (CMV) and EBV (Table S5). Finally, VSTs may also be used to treat viral infections that are not related to cancer and/or transplant, such as HIV (NCT03212989) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (NCT04406064). VSTs are usually derived from an allogeneic source (70%) (Figure 3(b) (i)), as they are often isolated from transplant donors to ensure compatibility with HSCT recipients, or from convalescent donors for the treatment of viral infections. Some VSTs have already progressed to clinical trials in Phases 3 and 4.

Unlike VSTs, TAA-Ts are mostly autologous (74%) (Figure 3(b) (ii)). NY-ESO-1, PRAME, and survivin are the most commonly named targets; however, we should note that the majority of the targets were not specified in the trial listings. That is, many trials indicated that the cells could be personalized for each patient, with the therapy consisting of a mixture of cells designed to target multiple TAAs. This explains the benefit of autologous sourcing, as these mixed populations of activated T cells can be isolated directly from the patient. About two thirds of these therapies are designed to treat solid tumors (Figure 3(b) (ii) bar), arising from the ability of endogenous TCRs to recognize intracellular antigens via display on MHC molecules. There are multiple trials currently in Phase 2 (NCT03093350), although TAA-Ts have yet to progress to Phase 3.

The remaining NGM cell trials with N/A receptors (40% of all NGM) comprise a broad spectrum of T-cell subtypes and use T cells that do not have a specific antigen target (Figure 3(b) (iii)). These untargeted NGM cells are often derived from a general, unsorted population of peripheral T cells. Of these trials, a total of six have progressed to Phase 2/3 or Phase 3 (NCT03944980, NCT02999854). Other therapies in earlier clinical stages (Phases 1 and 2) consist of more specific populations. For example, TILs are being explored as a NGM solid tumor-targeting therapy (NCT03374839). Tregs, on the other hand, are primarily being used for the treatment of GVHD and autoimmune disorders. Based on our analysis, they comprise a large portion of the NGM cells without specific targets (28/72, 39%) and contribute mainly to the transplant-related disorders—graft versus host diseases (TrDG) indication (NCT01903473, NCT02749084). Tregs promote immune tolerance in both antigen-dependent and independent manners, including the secretion of anti-inflammatory cytokines to dampen immune-mediated tissue damage.65

### 4.2 Stem cells

Stem cells have persisted at the forefront of the clinical landscape for cell therapies due to their high multipotency, which enables their differentiation into various types of mature cells with a broad range of functions. Currently, stem cells account for 36% of total trials with applications covering 10 major indications (Figure 2). A representative selection of these trials is provided in Table 3. In our analysis, we first...
| GM Sub-type | Gene of Interest | Source | Indication | Name (Sponsor) | Route | Trial number | Other trials and/or notes |
|------------|-----------------|--------|------------|----------------|-------|--------------|--------------------------|
| No MSC | N/A | Autologous | Osteoarthritis | JOINTSTEM® (Nature Cell Co. Ltd.) | IA | NCT03990805 (Phase 3) | NCT03509025 (Phase 2/3), NCT04427930 (Phase 3), NCT04368806 (Phase 2/3) |
| No MSC | N/A | Autologous | Alzheimer's disease | HB-adMSCs (Hope Biosciences) | IV | NCT04228666 (Phase 1/2) | None |
| No MSC | N/A | Allogeneic | Parkinson's disease | N/A (The University of Texas Health Science Center, Houston) | IV | NCT04506073 (Phase 2) | None |
| No MSC | N/A | Autologous | Huntington's disease | Cellavita-HD (Azidus Brasil) | IV | NCT03252535 (Phase 2) | NCT04219241 (Phase 2/3), NCT02728115 (Phase 1) |
| No NSC | N/A | Allogeneic | Parkinson's disease | ISC-hpNSC (Cyto Therapeutics Pty Limited) | ICe | NCT02452723 (Phase 1) | None |
| No MSC | N/A | Allogeneic | Rheumatoid arthritis | FURESTEM-RA Inj. (Kang Stem Biotech Co., Ltd.) | IV | NCT03618784 (Phase 1/2) | None |
| No MSC | N/A | Allogeneic | Type 1 diabetes | N/A (Medical University of South Carolina) | IV | NCT04061746 (Phase 1) | None |
| No MSC | N/A | Autologous | Multiple sclerosis | NurOwn® (MSC-NTF) (Braintree-Cell Therapeutics) | IV | NCT03797718 (Phase 2) | Neurotrophic factor secretion |
| No MSC | N/A | Allogeneic | Systemic lupus erythematosus | N/A (Medical University of South Carolina) | IV | NCT02631663 (Phase 2) | None |
| No NSC | N/A | Allogeneic | Multiple sclerosis | hNSCs (IRCCS San Raffaele) | ITh | NCT03269071 (Phase 1) | None |
| No MSC | N/A | Allogeneic | Ovarian cancer | N/A (Mayo Clinic) | IP | NCT02068794 (Phase 1/2) | Oncolytic measles virus encoding thyroidal sodium iodide symporter as payload |
| No MSC | N/A | Allogeneic | Non-small cell lung cancer | MSCTRAIL (University College London) | IV | NCT03290763 (Phase 1/2) | TRAIL as payload |
| GM | Sub-type | Gene of interest | Source | Indication | Name (Sponsor) | Route | Trial number | Other trials and/or notes |
|----|----------|------------------|--------|------------|----------------|-------|--------------|---------------------------|
| Yes | HSC      | shI; TAR; CCR5RZ | Unknown| AIDS-related liquid cancers | N/A (City of Hope Medical Center) | IV    | NCT02337985 (Phase 1) | HSC transfected by lentiviral vector rHIV7-shI-TAR-CCR5RZ to express i) a short hairpin RNA (shRNA) targeted to an exon of the HIV-1 genes tat/rev(shI), (ii) a decoy for the HIV TAT reactive element (TAR), and (iii) a ribozyme targeting the host cells CCR5 chemokine receptor (CCR5RZ) |
| No  | HSC      | N/A              | Autologous| Non-Hodgkin lymphoma | N/A (Novartis Pharmaceuticals) | IV    | NCT03570892 (Phase 2/3) | None |
| No  | HSC      | N/A              | Allogeneic| Pediatric AML | N/A (Samsung Medical Center) | IV    | NCT02848183 (Phase 2) | None |
| No  | HSC      | N/A              | Autologous| Brain and CNS tumors | N/A (St. Jude Children's Research Hospital) | IV    | NCT0085202 (Phase 3) | None |
| No  | HSC      | N/A              | Autologous| Germ cell tumors | N/A (Masonic Cancer Center, University of Minnesota) | IV    | NCT00432094 (Phase 2) | None |
| No  | HSC      | N/A              | Allogeneic| Solid tumors | N/A (M.D. Anderson Cancer Center) | IV    | NCT04530487 (Phase 2) | None |

Blood disorders (n = 55)

| No  | HSC      | N/A              | Allogeneic| Thalassemia major | N/A (First Affiliated Hospital of Guangxi Medical University) | IV    | NCT0409525 (Phase 4) | None |
| Yes | HSC      | β-globin         | Allogeneic| Sickle cell disease | N/A (bluebird bio) | IV    | NCT04293185 (Phase 3) | NCT02906202 (Phase 3 for thalassemia); Lentiviral vector Lentiglobin BB305 encoding functional β-globin |
| Yes | HSC      | Bcl11a           | Autologous| Sickle cell disease | CTX001 (Vertex Pharmaceuticals Incorporated) | IV    | NCT03745287 (Phase 1/2) | NCT03655678 (Phase 1/2); CRISPR/Cas9 editing to knock out enhancer region of Bcl11a |

Transplant-related diseases (n = 24)

| No  | HSC      | N/A              | Allogeneic| Kidney transplant rejection | MDR-102 (Medeor Therapeutics, Inc.) | IV    | NCT03605654 (Phase 2/3) | None |
| No  | MSC      | N/A              | Allogeneic| Steroid-resistant severe aGvHD | N/A (Fujian Medical University) | IV    | NCT03631589 (Phase 2/3) | None |
| GM Sub-type | Gene of interest | Source | Indication | Name (Sponsor) | Route | Trial number | Other trials and/or notes |
|-------------|-----------------|--------|------------|----------------|-------|-------------|--------------------------|
| **Nonautoimmune inflammatory diseases (n = 44)** | | | | | | | |
| No MSC | N/A | Allogeneic | Non-COVID-19 ARDS | HC016 (Histocell, S.L.) | IV | NCT04289194 (Phase 1/2) | None |
| No MSC | N/A | Allogeneic | COVID-19 | Remesmecel-L (Mesoblast, Inc.) | IV | NCT04371393 (Phase 3) | None |
| No MSC | N/A | Autologous | COPD | N/A (Mayo Clinic) | IV | NCT04047810 (Phase 1) | None |
| No MAPC | N/A | Allogeneic | Non-COVID-19 ARDS | HLCM051 (Healios K.K.) | IV | NCT03807804 (Phase 2) | None |
| **Trauma (n = 31)** | | | | | | | |
| No MSC | N/A | Autologous | Spinal cord injury | N/A (Mayo Clinic) | ITh | NCT04520373 (Phase 2) | None |
| No MSC | N/A | Allogeneic | Ischemia reperfusion injury | N/A (Mayo Clinic) | IAd | NCT04388761 (Phase 2) | None |
| No MSC | N/A | Autologous | Traumatic brain injury | HB-adMSCs (Hope Biosciences) | IV | NCT04063215 (Phase 1/2) | None |
| No MSC | N/A | Allogeneic | Heart failure | N/A (MD Anderson Cancer Center) | IV | NCT02408432 (Phase 1) | None |
| No MSC | N/A | Allogeneic | Acute-on-chronic liver failure | allo-APZ2-ACLF (RHEACELL GmbH & Co. KG) | IV | NCT03860155 (Phase 1/2) | None |
| **Other (n = 70)** | | | | | | | |
| Yes HSC | CCR5 | Autologous | DOCK8 deficiency | SB-728mR-HSPC (City of Hope Medical Center) | IV | NCT02500849 (Phase 2) | CCR5 modified by zinc finger nuclease |
| Yes HSC | ADA | Autologous | SCID due to ADA deficiency | OTL-101 (Great Ormond Street Hospital for Children NHS Foundation Trust) | IV | NCT03765632 (Phase 1/2) | TYF-ADA lentiviral vector encoding functional ADA gene |
| Yes HSC | | Autologous | Cerebral adrenoleukodystrophy | Elivaldogene autotemcel (bluebird bio) | IV | NCT03852498 (Phase 3) | |
| Yes HSC | CD18 | Autologous | Leukocyte adhesion deficiency | RP-L201 (Rocket Pharmaceuticals) | IV | NCT03812263 (Phase 1/2) | NCT03825783 (Phase 1); Delivery of lentiviral vector Chim-CD18-WPRE to induce CD18 expression in mature granulocytes |
categorized stem cell trials by cell subtype, including HSCs (44%), MSCs (46%), neural stem cells (NSCs, 2%), bone marrow-derived stem cells (BMDSCs, 3%), and others (Figure 4). Cells in the HSC and MSC categories were further classified according to indications and features like genetic modification.

4.2.1 | HSCs

HSCs comprise 44% of the current stem cell trials (Figure 4(a)). These trials apply HSCT, which has been widely utilized in the clinic since it was first reported in 1957. The basic process for HSCT includes collection of mobilized stem cells from peripheral blood or cord blood, ex vivo purification and engineering of the cells, and finally infusion. Prior to transplantation, patients undergo a regimen of chemotherapeutics, broadly classified into myeloablative and reduced intensity conditioning (RIC), to deplete native lymphocytes in the bone marrow. This conditioning step is required for the successful engraftment of the infused cells. The choice of regimen depends on parameters such as disease severity, risk, age group, and other factors. RIC leads to reduced neutropenic periods, speedier engraftment, and improved recovery of the immune system compared to myeloablative conditioning. As a result, RIC has widened the potential applications of HSCT to a greater patient population, especially older patients. However, post-transplant relapse and GvHD remain challenges, and these challenges are further discussed in Section 5.

HSCs are of great importance in the generation of a variety of blood cells and therefore have substantial implications in the genesis and treatment of hematological conditions. Accordingly, the majority of active HSC clinical trials (69%) are applied for various hematological malignancies and nonmalignant blood disorders associated with RBCs (BD w/RBCs) (Figure 4(a)), with remaining indications including solid cancers, nonmalignant blood disorders associated with white blood cells (BD w/WBCs), and immunodeficiency, autoimmune, and transplant-related disorders. HSC source also plays a key role in the therapeutic outcome, and 61% of HSC trials use allogeneic cells (Figure 4(a)). This can be attributed to the fact that the most common goal of HSCT is to replace the patients’ malignant immune cells with healthy donor HSCs, which are usually derived from a complete or partial HLA-matched donor or “off-the-shelf” cord blood. On the contrary, GM HSC therapies apply autologous cells more frequently because disease-causing mutations of patients’ own cells are corrected by genetic engineering; autologous cells are associated with a lower risk of transplant rejection and thus are better tolerated by patients. In the following analysis, we present HSC trials according to disease indication and discuss the unique features of HSCs in each category.

The predominant indication of HSC trials is liquid cancers (51% of HSC trials). The majority of these trials (71%) use allogeneic cells that can differentiate into healthy blood cells and directly reconstitute the bone marrow (Figure 4(a)(i)). Notably, 12% of these trials are in Phase 3 or 4 (Figure 4(a)(iii)). This landscape of the Phase of HSC trials may reflect the application of well-established HSCT methodology in...
nearly all trials, where only variations in pre- or post-transplant therapeutic regimens are examined. On the other hand, GM HSCs are not yet FDA approved and are being investigated in the clinic for safety and efficacy. One example is a pair of trials using GM HSCs for the treatment of acquired immunodeficiency syndrome (AIDS)-related liquid cancers (NCT02337985 and NCT01961063). Specifically, these HSCs were transduced with lentiviral vector rHIV7-shI-TAR-CCR5RZ, with the mechanism of action including (i) blocking the transcription of HIV genes, (ii) binding to the protein that is essential for HIV replication, and (iii) catalyzing the CCR5 receptor that is required for viral entry into the host cells. This autologous therapy has the potential to reconstitute the bone marrow with autologous, non-neoplastic cells.

The next focus of HSC trials is nonmalignant blood disorders associated with RBCs (BD w/RBCs) (18% of HSC trials) for diverse clinical indications including sickle cell disease, anemia, and thalassemia, among others. While NGM HSC trials mainly employ allogeneic cells (64%), GM HSC therapies exclusively employ autologous cells (36%) (Figure 4(a)(i) and (iii)). These autologous GM HSCs can be modified ex vivo to express correct sequences of target genes and thus generate cells with functional proteins. For example, the GM HSC product Zynteglo™ consists of autologous cells endowed with functional β-globin by lentiviral transduction. It was approved for the treatment of transfusion-dependent thalassemia by the EMA in 2019 and is currently being investigated for related indications including sickle cell disease (NCT04293185) and β-thalassemia (NCT02906202). Another active area of HSC therapy is solid tumors (9% of HSC trials). Interestingly, 58% of these clinical trials utilize autologous cells (Figure 4(a)(ii)), unlike the trials for blood cancers. This is not surprising because, in the case of solid tumors, the goal of HSC therapy is to bolster the existing immune system. Notably, all of the Phase 3 clinical trials for solid tumors (26%) are for the treatment of either brain metastases or neuroectodermal cancers (Figure 4(a)(iii)). The potential of HSCs to home to brain tumors has been shown in preclinical studies, although the mechanism remains unexplained.
HSC-based therapies are also clinically investigated for non-malignant blood disorders associated with WBCs (BD w/WBCs) and immunodeficiency disorders, such as Wiskott-Aldrich syndrome (WAS), severe combined immunodeficiency (SCID), and leukocyte adhesion disorder (LAD). 69% of these trials utilize GM HSCs, as the intention is to correct mutations responsible for disease (Figure 4(a)(iii)). While most of the trials (95%) are still in Phase 1 or 2 (Figure 4(a)(ii)), there is one trial in Phase 3, where elivaldogene autotemcel, a therapy that uses GM HSCs endowed with functional human adrenoleukodystrophy protein, is used to treat cerebral adrenoleukodystrophy (NCT03852498). HSCs are also being explored for the treatment of autoimmune disorders in a small subset of trials (4%) (Figure 4(a)). The specific indications are diverse and include multiple sclerosis (MS), systemic scleroderma, and Crohn’s disease. While the number of trials in this area is low, the relative proportion of late stage trials is high; based on our analysis, over one-third of the trials are in at least Phase 3 and one trial is in Phase 4. The majority of these late-stage studies test the efficacy of autologous HSCT compared to the current clinical regimens, such as alemtuzumab for MS.

4.2.2 | MSCs

MSC therapies make up 46% of total current stem cell clinical trials (Figure 4(b)). MSCs are derived from multiple tissues, including bone marrow, adipose tissue, the umbilical cord, Wharton’s jelly, and the placenta. Interestingly, the majority (65%) of the investigated MSC therapies are allogeneic, reflecting the trend of next-generation “off-the-shelf” manufacturing (Figure 4(b)). While most of the investigated trials are in Phase 1 or 2, 6% of MSC trials have reached Phase 3 or 4. While GM cells are widely utilized in certain cell therapies (T cells in particular), the majority (> 98%) of the analyzed MSC trials use NGM MSCs. The widespread use of NGM cells may arise from their inherently multipotent nature, which enables a number of possible biological functions without genetic modification. Notably, four of the analyzed trials use GM MSCs, reflecting recent efforts to improve MSCs’ innate functions or provide them with new functions such as secretion of therapeutic proteins. Current MSC trials cover a wide variety of indications, including degenerative diseases, autoimmune diseases, and cancer (Figure 4(b)). However, the majority of MSC trials can be broadly classified into two major categories based on their key mechanism: tissue repair/regeneration for degenerative diseases and trauma, and immunomodulation for autoimmune diseases, non-autoimmune inflammatory diseases, infectious diseases, and transplant-related diseases. Trials that do not fall into these categories cover other indications such as cancer, cardiovascular diseases, and blood disorders.

The potential of MSCs to differentiate into cells across endodermal, mesodermal, and ectodermal lineages has been widely investigated in preclinical and clinical settings. Thus, a large portion of the current trials are focused on tissue repair or regeneration applications (32%), with the most prominent being degenerative diseases (24%) (Figure 4(b)). Based on our analysis, 30 trials use MSCs to repair cartilage for the treatment of osteoarthritis, which was one of the earliest indications for MSC therapies. As a representative example, JOINTSTEM, an autologous adipose-derived MSC therapy, demonstrated suitable safety and preliminary efficacy profiles and is currently in two Phase 3 trials for osteoarthritis (NCT03990805, NCT04427930). Neurodegenerative disease is another particularly active area, with seven MSC trials underway for Alzheimer’s disease, two for Parkinson’s disease, and three for Huntington’s disease. Based on our analysis, all but one of these neurodegenerative disease trials are still in early stages (Phase 1 or 2), with one exception reaching Phase 2/3. This Phase 2/3 trial involves the autologous MSC therapy, Cellavita-HD, which has previously demonstrated promising safety and preliminary efficacy profiles for Huntington’s disease (NCT04219241). Other degenerative disease indications of MSC therapy include disk degeneration, aging frailty, and several others. Trauma is another important indication for MSC tissue repair applications, with 23 active trials (8%) (Figure 4(b)) underway for traumatic brain injury, spinal cord injury, acute kidney injury, ischemia reperfusion injury, and others. While the therapeutic mechanism of MSCs in these degenerative diseases seems to be related to their multipotent differentiation capabilities, their immunomodulatory potential may also play an important role.

Immunomodulatory capabilities of MSCs can also be leveraged as the primary mechanism for disease management. About 49% of the analyzed MSC trials are focused on this application for the treatment of immune-related diseases. Autoimmune diseases, as the second largest disease category of all MSC therapies (18%) (Figure 4(b)), encompass rheumatoid arthritis, type 1 diabetes, MS, systemic lupus erythematosus, and others. Although all of these trials are in the early stages (Phase 1 or 2), the large number of trials is indicative of the overall promise of MSCs for autoimmune disease applications. Non-autoimmune inflammatory disease is another important area for MSC immunomodulation clinical studies, with 14% of all MSC trials (Figure 4(b)) underway for the treatment of bronchopulmonary dysplasia, liver cirrhosis, acute and chronic pancreatitis, chronic obstructive pulmonary disease (COPD), and glomerulonephritis. About 13% of active MSC trials are for infectious diseases (Figure 4(b)). With the ongoing COVID-19 pandemic, MSC-based therapies have already entered the clinic for the treatment of SARS-CoV-2 infections, with two trials having already entered Phase 2/3. As a representative example, Remestemcel-L is an allogeneic MSC product that was initially investigated for pediatric aGvHD and is now being repurposed for the treatment of COVID-19 ARDS in a Phase 3 study (NCT04371393). MSC therapy for transplant-related diseases also leverages the immunomodulatory capacity of MSCs, with 4% of all MSC trials underway to treat aGvHD and organ transplant rejection, particularly of the liver, kidney, and lungs (Figure 4(b)).

Most of the clinical efforts so far have been mainly focused on employing the multipotent capability of NGM MSCs for diverse indications. However, in recent years, extensive preclinical studies have looked into GM MSCs, especially for the indication of cancer. Indeed, MSCs have been engineered to produce anticancer therapeutic proteins, such as TNF-related apoptosis-inducing ligand (TRAIL)
and thrombospondin-1, in preclinical studies. These new advances are reflected in the clinical trial landscape, where allogeneic MSCs engineered to express TRAIL (MSCTRAIL) are currently being investigated as a therapeutic for inoperable lung adenocarcinomas (NCT03298763).

4.2.3 Other stem cells

Other types of stem cells account for only 10% of all current clinical stem cell trials, far fewer trials than either HSCs or MSCs (Figure 4(c-e)). These stem cells include NSCs (Figure 4(c)), bone marrow-derived stem cells (Figure 4(d)), cardiac stem cells, endothelial progenitor cells, LSCs, and multipotent adult progenitor cells, among others (Figure 4(e)). The relative rarity of these stem cell types in the clinic compared to HSCs and MSCs may be due to a variety of factors such as (i) the biological functions of these stem cells are not as diverse as those of HSCs and MSCs, and (ii) availability/manufacturing of these stem cells are more challenging. Of note, the investigated applications for these subtypes are relatively narrow. For example, specific indications of NSCs include astrocytoma, glioma, Parkinson’s disease, retinitis pigmentosa, and spinal cord injury. Notable applications of other subtypes include lung stem cells for idiopathic lung fibrosis and interstitial lung diseases, retinal progenitor cells for retinitis pigmentosa, and multipotent adult progenitor cells for immunomodulatory applications.

4.3 Dendritic cells

DC vaccines are an active area of clinical study, with 93% of trials investigating their use for cancer immunotherapy (Figure 2). A representative selection of DC trials is shown in Table 4. DC clinical trials have applications for a range of both solid and liquid tumors (93%) and the remainder for autoimmune disorders, infectious diseases, and transplant-related disorders. Based on our analysis, all Phase 3 trials and most Phase 1 and 2 trials are for cancer indications, although 6% of the current Phase 1 and 2 trials investigate DC vaccines for the treatment of multiple sclerosis, type I diabetes, rheumatoid arthritis, HIV, COVID-19, and transplant-related diseases. Like the approved products (three globally, with one in the United States), the majority of DC trials (89%) use autologous cells (Figure 2). However, allogeneic cells have demonstrated potential for indications such as leukemia (NCT03679650) and living donor liver transplant (NCT04208919). The trial space for DCs is generally diverse, owing to the investigation of many different ex vivo cell pretreatments. Ex vivo pretreatment of DCs primarily involves antigen priming, which is necessary to expose the cells to tumor antigens so that they can present antigen-specific peptides on MHC class II to the patient’s T cells in the lymph nodes. The most common method for exposing the cells to tumor antigens is ex vivo incubation and loading (also frequently termed “pulsing”) with specific antigens, tumor lysate, or RNA. Another novel method involves direct fusion of the DCs with patient-specific tumor cells obtained via a biopsy. In six clinical trials involving RNA delivery, electroporation is used to promote ex vivo loading in DCs. These cell modifications are summarized in Figure 5(a). (i).

Other distinguishing aspects of the DC vaccine trial space include the routes of administration, addition of immune stimulatory molecules, and other combination drug regimens. The most common route of administration for DC vaccines is intradermal injection (45%), while intravenous (22%), subcutaneous (11%), and intranodal (11%) injections are also used (Figure 5(a) (i)). Co-administered stimulatory molecules including growth factors, cytokines, and monoclonal antibodies can promote the expansion and trafficking of DCs to the lymph node (e.g., GM-CSF) (NCT03334305), activate T and NK cells (e.g., IL-2) (NCT04166006), or sensitize cancer cells to cytotoxic T cells (e.g., anti-PD-1, anti-PD-L1) (NCT01067287, NCT02677155) (Figure 5(a) (iii)). Other common accompanying therapies include chemotherapeutics (NCT02366728, NCT02503150), other cell types (e.g., stem cells (NCT03334305), T cells (NCT01759810), immunomodulators (NCT04208919), and radiation (NCT03970746).

4.4 NK cells

NK cells have drawn increased attention over the past few years due to their natural cytotoxic functions, non-MHC restricted activity, and “off-the-shelf” use capability. These features allow them to offer a potent alternative to T-cell therapy. Currently, NK cell trials occupy 7% of total cell therapy trials (Figure 2), with a representative selection of these trials listed in Table 5. NK cell trials utilize NK cells of various origins, including allogeneic sources (53%), autologous sources (27%), NK cell lines (15%), and stem cell-derived (allogeneic) sources (5%) (Figure 2). The frequent use of allogeneic NK cells may be due to the therapeutic effects associated with the killer-immunoglobulin receptor (KIR)-HLA mismatch. Specifically, the identification of self-MHCs by KIRs provides inhibitory signals to NK cells to halt cytotoxic functions; in the case of adoptive transfer of allogeneic cells, these signals are absent. In addition, when allogeneic NK cells simultaneously encounter foreign MHCs and disease-associated antigens on target cells, activation signals are triggered. This combination of missing inhibitory signals and multiple activating signals elicits the cytotoxic function of allogeneic NK cells against diseased cells. Although peripheral blood NK cells are still the major source in NK-cell therapy (80%, combined autologous and allogeneic) (Figure 2), there are translational challenges due to limited availability (i.e., NK cells only account for 5%-10% of peripheral white blood cells) and difficulty of expansion ex vivo. Induced pluripotent stem cell (iPSC)/HSC-derived cell products and cell lines have been introduced in the clinic to tackle these challenges by providing a sufficient cell source and eliminating the barrier of ex vivo expansion.

Several NK-cell subtypes are applied in NK-cell trials, encompassing primary NK cells, CAR-NK cells, CILs, NK cell lines (NK-92), and iPSC/HSC-derived NKs (Figure 5(b) (i)). Most NK cell trials (66%) use unmodified primary NK cells and leverage their intrinsic cytotoxic function (Figure 5(b) (i)). CAR-NK therapies (12%) have gained attention over the past few years due to encouraging results.
| GM | Priming materials | Source | Indication | Name (Sponsor) | Route | Accompanying therapies | Trial number | Other trials and/or notes |
|----|-------------------|--------|------------|----------------|-------|------------------------|--------------|-------------------------|
| Cancer (n = 127) | | | | | | | | |
| No | Tumor-specific antigens | Autologous | Glioblastoma | N/A (NeuroVita Clinic) | SC | (co) HSCs, cytotoxic lymphocytes, GM-CSF | NCT01759810 (Phase 2/3) | None |
| Yes | Tumor RNA | Autologous | Uveal melanoma | N/A (University Hospital Erlangen) | IV | N/A | NCT01983748 (Phase 3) | None |
| Yes | pp65-LAMP mRNA | Autologous | Glioblastoma | N/A (Duke University Medical Center) | ID | (pre) Tetanus, basilixumab, (post) Temozolomide | NCT02366728 (Phase 2) | None |
| No | Tumor cell lysate | Autologous | Metastatic colorectal cancer | APDC (Second Military Medical University) | IV | (co) Chemotherapy (oxaliplatin, 5-fluorouracil, leucovorin) | NCT02503150 (Phase 3) | None |
| Yes | TT-RNA | Unknown | Glioma | TTRNA-DC (University of Florida) | ID | (pre) Chemotherapy (temozolomide), (co) GM-CSF, tetanus, autologous HSCs | NCT03334305 (Phase 1) | NCT03396575 (Phase 1) |
| No | Tumor cell lysate | Autologous | Mesothelioma | MesoPher (Amphera B.V.) | Unk | (co) Best supportive care | NCT03610360 (Phase 2/3) | None |
| No | PA2024 | Autologous | Prostate adenocarcinoma | Sipuleucel-T (Dendreon) | IV | (co) GM-CSF | NCT03686683 (Phase 3) | None |
| No | Synthetic peptides | Cell line | Non-small cell lung cancer | PDC lung01 (PDC’line Pharma SAS) | IV | (pre) Radiation, (post) Pemetrexed | NCT03970746 (Phase 1/2) | None |
| No | Tumor-specific antigens | Autologous | Glioblastoma | ADCTA (Safe Save Medical Cell Sciences & Technology Co., Ltd.) | SC | (co) Bevacizumab | NCT04277221 (Phase 3) | None |
| No | AML cells | Allogeneic | AML | N/A (Dana Farber Cancer Institute) | SC | (co) GM-CSF, (post) Decitabine | NCT03679650 (Phase 1) | None |
| No | Loaded with tumor homogenate | Autologous | Head and neck tumors, neuroendocrine tumors, soft tissue sarcoma | N/A (Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori) | ID | (post) IL-2 | NCT04166006 (Phase 2) | None |
| No | Fused with myeloma cells | Autologous | Multiple myeloma | N/A (Beth Israel Deaconess Medical Center) | Unk | (co) Anti-PD-1 | NCT01067287 (Phase 2) | None |
| No | None | Autologous | Follicular lymphoma | N/A (Oslo University Hospital) | IN | (pre) Radiation, anti-PD-L1 immunotherapy, (co) Rituximab, GM-CSF, pembrolizumab, (post) Pembrolizumab | NCT02677155 (Phase 2) | None |

Transplant-related diseases (n = 3)

| No | N/A | Allogeneic | Liver transplantation | DCreg (University of Pittsburgh) | IV | Standard-of-care immunosuppression, weaned after 1 week | NCT04208919 (Phase 1/2) | Usage of DCreg |
following the recent approval of CAR-T products (Figure 5(b) (i)). CAR-NK cells are generally regarded as safer than CAR-T cells due to their more limited persistence in circulation. CAR-NK cells are also less likely to induce severe side effects because CAR-NK cells usually produce IFN-$\gamma$ and GM-CSF upon activation, while CAR-T cells produce a set of cytokines (IL-1a, IL-2, IL-6, TNF-$\alpha$, MCP-1, IL-8, IL-10, IL-15, and others) that have been shown to cause cytokine release syndrome and severe neurotoxicity. CAR-NK cell therapies are used for (i) hematological malignancies expressing CD19 (NCT03056339), BCMA, and CD 22; (ii) solid tumors with targets including ROBO-1, PSMA, and mesothelin; and (iii) COVID-19 with ACE-2 as a target (NCT04324996). Another major cell class is CIKs (11%) (Figure 5(b) (i)), which have an NK-T hybrid cell phenotype and operate in a non-MHC restricted fashion. CIKs are also referred to as type II NKT cells. An attractive feature of CIKs is that they can be induced and expanded ex vivo from PBMCs and cord blood mononuclear cells (CBMCs) via a combination of cytokines. Currently, one of the most advanced NK cell trials for malignant glioma (Phase 4) uses CIKs as the intervention (NCT02496988). The NK-92 cell line (7%) is another promising candidate due to its ease of expansion and transfection in comparison to primary NK cells (Figure 5(b) (i)). It has been validated as safe in many Phase 1 trials and is being currently used in advanced trials (NCT02727803, NCT02465957). Finally, iPSC/HSC-derived cells (4%) are being explored to overcome the limit of NK cell availability from PBMCs (Figure 5(b) (i)). For example, CYNK-001, an HSC-derived NK product, is currently being investigated in a Phase 1/2 clinical trial for the treatment of COVID-19 (NCT04365101).

The main indication of NK-cell therapy is cancer (95%), followed by infectious diseases (e.g., COVID-19 and HIV) (4%) (Figure 2). A large proportion of NK-cell trials are for hematologic malignancies, with 21% for acute/chronic myeloid leukemia (AML/CML) and 11% for lymphoma (Figure 5(b) (ii)). Notably, despite limited information regarding tumor infiltration by NK cells, there are more clinical trials investigating NK-cell therapy for solid cancers than liquid cancers. These trials against solid tumors often use CAR and combination therapy approaches to improve targeting and overcome the immunosuppressive tumor microenvironment in cancers such as glioblastoma (NCT03383978). Interestingly, based on our analysis, augmenting NK-cell therapy with co-administered or postadministered therapeutics is a strategy adopted by a considerable portion of the NK trials (35%). Antibodies (NCT04074746) and cytokines (NCT03050216) are the most used supporting therapeutics (29% for both), followed by chemotherapeutics (NCT02496988), and a combination of those (NCT03778619) (Figure 5(b) (iii)).

### 4.5 | Mononuclear cells

Compared to the other cell types, there are fewer clinical trials for mononuclear cells (2% of the total trials) (Figure 2). As stated previously, we refer to mononuclear cells as belonging to one of the following cell populations: monocytes (11% of mononuclear cell trials), macrophages (0% of mononuclear cell trials), BMMCs (52% of...
mononuclear cell trials), or PBMCs (37% of mononuclear cell trials) (Table 6). The most common indications are cardiovascular disease (39%) and cancer (29%), with some applications for trauma (14%) (Figure 2). These trials are almost evenly distributed across Phase 1 (38%), Phase 2 (33%), and Phase 3 (30%) (Figure 2). Most (89%) of these trials use autologous cells, likely due to the highly regulated immune functions of these cell types (Figure 2).

There are many preclinical studies that use monocytes and macrophages as therapies, therapeutic targets, or both, most often for the treatment of cancer, autoimmune diseases, and other inflammatory diseases.96-99 However, translation to the clinic has been limited. For monocytes, two trials are indicated for central nervous system (CNS) disorders, while one trial is indicated for cancer. Notably, there are a number of studies where monocytes are separated via leukapheresis and subsequently differentiated into DCs for re-injection. Due to their highly plastic nature, monocytes are well-suited for ex vivo conditioning, which is used to induce phenotypic changes before re-injection (NCT02948426). While many trials use macrophage populations as a target for imaging agents or as an indicator of clinical outcomes, these cells are not currently being infused as an intervention.

BMMCs and PBMCs were also included in the clinical trial analysis. These groups are clinically useful because they invoke pleiotropic mechanisms, owing to the variety of distinct cell populations that are included. This allows, for example, the secretion of various remodeling factors to facilitate wound healing and regeneration.100 Similar to monocytes/macrophages, ex vivo conditioning allows for the induction of phenotypic changes (NCT02948426). It is also possible to enrich or deplete these mononuclear cells of certain cell populations, such as naïve T cells (NCT02942173) or B cells (NCT03939585). Other modifications include transfection with small interfering RNA (siRNA) (NCT03087591) and induction of specific receptors before re-infusion (NCT01697527). Combination therapies with stem cells are also being investigated (NCT03943940). Though the trial space for mononuclear cells is in its early stages, the multifunctional properties of these cells make them an attractive avenue for a diverse array of future therapies.

4.6 Red blood cells and platelets

Clinical trials are also being conducted on the intravenous infusion of donor blood products, such as packed RBCs, whole blood, and platelets. Here, we focus our scope on the trials that use a single cell type, either RBCs (2% of the total trials) or platelets (0.4% of the total trials)
### TABLE 5 Examples of current clinical trials for natural killer cell therapies, grouped by indication

| GM | Sub-type | Target | Source | Indication | Name (Sponsor) | Route | Accompanying therapies | Trial number | Other trials and/or notes |
|----|----------|--------|--------|------------|----------------|-------|------------------------|-------------|--------------------------|
| **Liquid cancer (n = 42)** | | | | | | | | | |
| Yes | CAR | CD19 | Allogeneic | Lymphoma | N/A (M.D. Anderson Cancer Center) | IV | None | NCT03056339 (Phase 1/2) | Suicide gene |
| No | N/A | N/A | Allogeneic | Lymphoma | N/A (M.D. Anderson Cancer Center) | IV | None | NCT04074746 (Phase 1) | AFM13 bispecific antibody delivered as NK cell payload |
| No | N/A | N/A | Allogeneic | Lymphoma | MG4101 (Green Cross LabCell Corporation) | IV (co) IL-2, rituximab | None | NCT03778619 (Phase 1/2) | |
| No | N/A | N/A | Allogeneic | AML | N/A (M.D. Anderson Cancer Center) | IV | None | NCT01787474 (Phase 1/2) | None |
| No | N/A | N/A | Allogeneic | AML | UCB-NK (Radboud University) | IV (co) IL-2 | None | NCT04347616 (Phase 1/2) | None |
| No | N/A | N/A | Allogeneic | AML, MDS | N/A (Washington University School of Medicine) | IV (co) IL-2 | None | NCT01898793 (Phase 1/2) | None |
| No | NK-92 | N/A | Cell line | Leukemia, lymphoma, MDS | N/A (M.D. Anderson Cancer Center) | IV | None | NCT02727803 (Phase 2) | None |
| No | N/A | N/A | Allogeneic | AML | N/A (St. Jude Children’s Research Hospital) | IV | None | NCT00703820 (Phase 3) | None |
| **Solid cancer (n = 68)** | | | | | | | | | |
| No | CIK/NKT | N/A | Autologous | Glioma | N/A (The First People's Hospital of Changzhou) | IV (co) Temozolomide | NCT02496988 (Phase 4) | None |
| Yes | CAR NK-92 | HER2 | Cell line | Glioblastoma | NK-92/5.28.z (Johann Wolfgang Goethe University Hospital) | ICr | None | NCT03383978 (Phase 1) | None |
| No | N/A | N/A | Allogeneic | Glioblastoma | CYNK-001 (Celularity, Inc.) | IV, IT | None | NCT04489420 (Phase 1) | None |
| No | N/A | N/A | Autologous | Hepatocellular carcinoma | IKC (Ivy Life Sciences, Co., Ltd) | IV | None | NCT03592706 (Phase 2/3) | None |
| No | CIK/NKT | N/A | Autologous | Cholangiocarcinoma | N/A (The First People’s Hospital of Changzhou) | IV | None | NCT02482454 (Phase 2/3) | None |
| No | NK-92 | N/A | Cell line | Merkel cell carcinoma | aNK (NantKwest, Inc.) | IV (co) ALT-803 | NCT024695957 (Phase 2) | None |
| No | N/A | N/A | Autologous | HER2/EGFR+ cancer | SNK01 (NKMax America, Inc.) | IV (co) Trastuzumab, cetuximab | NCT04464967 (Phase 1/2) | None |
| No | N/A | N/A | Autologous | Solid tumors | N/A (Xuanwu Hospital, Beijing) | IV | None | NCT03634501 (Phase 1/2) | None |

(Continues)
Of all the clinical trials involving RBCs, the most common indications are blood disorders such as anemia (26%) and sickle cell disease (18%). In the majority of these trials, as well as those focused on treating hemorrhage, organ injury, and trauma, the unmodified RBCs themselves are the therapeutic of interest. While packed RBCs are already indicated for these conditions, current clinical trials investigate new infusion protocols (e.g., dosing frequency and amount), cell storage conditions, additional ex vivo cell processing steps for pathogen removal, and D-antibody matching.

RBCs are also indicated in other Phase 1 or Phase 2 trials with indications of cancer, lung cancer, breast cancer, and malaria infection, the latter of which involves RBCs infected ex vivo with the parasite *Plasmodium vivax* (*P. vivax*). These infected RBCs are administered to malaria-naïve volunteers to evaluate the safety of controlled blood-stage human *P. vivax* malaria infection and are expected to serve as a malaria vaccine in the future (NCT03797989). Notably, in seven trials, RBCs (two autologous and five allogeneic) are being used as drug carriers to carry and deliver membrane-bound (NCT04137692) or encapsulated cargoes (NCT03563053) to a site of interest. In all RBC trials, the platelets are administered intravenously. As with RBCs, new dosing regimens for platelet transfusions are also investigated. One distinct application of platelets in clinical trials is their co-administration alongside a thrombolytic drug in platelet-deficient patients (NCT02074436).

4.7 | Microbes

Forty-eight microbe-based clinical trials were identified (3% of the total trials) (Figure 2) and separated into four main categories based upon consortia-based/single strain-based therapy status and indication (Table 8).\(^4,33,101\) Undefined, consortia-based therapies consist of microbes collected from healthy patient stool banks.\(^102,103\) The resulting microbe therapeutic ranges from unpurified material stripped only of harmful components (e.g., viruses, pathogens) to material stripped of several species in order to isolate specific microbial phyla with some, or all, individual species remaining unidentified. These undefined mixtures are most similar to those used in FMT, however, the therapeutic is typically administered via oral capsules.\(^102,103\) Since FMTs fall under the category of a clinical procedure\(^101\) and are not being developed as drug products by independent pharmaceutical companies, FMT clinical trials were not included, as we determined them to be out of the scope of this review (a search on clinicaltrials.gov revealed over 900 hits for the term “fecal microbiota transplant”). Defined, consortia-based therapies are similar in that multiple strains of bacteria are orally delivered; however, the exact composition of the individual microbial species is known and is rationally selected. Many of the current consortia-based clinical trials are for *Clostridium difficile* infection and various gastrointestinal disorders. Consortia-based therapies

---

(Figure 2). A representative selection of these trials is given in Table 7.
| Cell Type | GM | Cell Modifications | Source | Indication | Name (Sponsor) | Route | Accompanying therapies | Trial number | Other trials and/or notes |
|------------|----|--------------------|--------|------------|---------------|-------|------------------------|--------------|--------------------------|
| Cancer (n = 8) |     |                     |        |            |               |       |                        |              |                          |
| Monocytes  | No | Stimulated with IFNs (Actimmune®, Sylatron™) | Autologous | Fallopian tube, ovarian, and peritoneal cancers | N/A (National Cancer Institute) | IP    | N/A                    | NCT02948426 | None                      |
| PBMC       | No | Depletion of naive (CD45RA+ ) T cells | Allogeneic | GvHD, infection | N/A (Federal Research Institute of Pediatric Hematology, Oncology and Immunology) | IV    | N/A                    | NCT02942173 | None                      |
| PBMC       | Yes| siRNA-transfected | Autologous | Solid tumors | APN401 (Wake Forest University Health Sciences) | IV    | N/A | siRNA silencing of cbl-b, an E3 ubiquitin ligase, to enhance activation of lymphocytes | NCT03087591 | None                      |
| PBMC       | Yes| Express NY-ESO-1 TCR | Autologous | Malignant neoplasms | N/A (Jonsson Comprehensive Cancer Center) | IV    | NY-ESO-1 peptide-pulsed dendritic cells (DC vaccine), IL-2 | NCT01697527 | None                      |
| PBMC       | No | Depletion of TCR-αβ T cells and B cells, enrichment of NK cells and TCRγδ T cells | Allogeneic | AML, ALL | N/A (Case Comprehensive Cancer Center) | IV    | N/A |  | NCT03939585 | None                      |
| Cardiovascular diseases (n = 11) |     |                     |        |            |               |       |                        |              |                          |
| BMMC       | No | N/A                 | Autologous | Heart failure | t2c001 (Johann Wolfgang Goethe University Hospital) | ICI   | N/A                    | NCT01693042 | None                      |
| BMMC       | No | N/A                 | Autologous | Heart failure (post-myocardial infarction) | N/A (American Heart of Poland) | ICI   | N/A                    | NCT02323620 | None                      |
| BMMC       | No | N/A                 | Autologous | Critical limb ischemia | REX-001 (Rexgenero Limited) | IAe   | N/A                    | NCT03111238 | None                      |
| Trauma (n = 4) |     |                     |        |            |               |       |                        |              |                          |
| BMMC       | No | N/A                 | Autologous | Traumatic brain injury | N/A (The University of Texas Health Science Center, Houston) | IV    | N/A                    | NCT01851083 | None                      |
| BMMC       | No | N/A                 | Autologous | Spinal cord injury | N/A (Shanghai Changzheng Hospital) | ITN   | N/A                    | NCT04528550 | None                      |

(Continues)
make up 44% of the current microbe clinical trials with 25% being defined consortia and 19% being undefined consortia (Figure 2).

Distinct from consortia-based therapies, single strain therapies are currently in clinical trials for indications including bacterial infections, inflammatory diseases, metabolic disorders, cancer, and others. Unlike consortia-based therapies, single strains offer more controlled and defined pathways for the discovery of specific pharmacological mechanisms of action, genetic engineering, formulation development, and consistent manufacturing, thereby reducing complexities for key regulatory considerations. Single, donor-derived strains constitute 56% of the microbe clinical trials. Of these, 21% were rationally selected for specific therapeutic action(s) as nongenetically engineered strains (Figure 2). These therapies are delivered in a variety of formulations and via a range of administration routes and include oral capsules, topical creams and sprays, and intravaginal suppositories. To enhance the natural functions of particular microbes, genetic engineering strategies can also be used to facilitate novel functions in the gut such as the metabolism of indigestible compounds or the delivery of therapeutic proteins and peptides directly to the gastrointestinal mucosa. Genetically engineered single strains of bacteria make up 35% of the current microbe clinical trials (Figure 2) with 72% of these trials indicated for cancer treatment. The strains used in these trials are often attenuated strains of pathogenic bacteria engineered to secrete tumor-specific antigens and are delivered via intratumoral injection.

A subset of microbe therapies in the clinic are administered in combination with immunotherapies. Based on our analysis, 57% (12/21) of all microbe-based trials for cancer applications involve combination treatments with immunomodulatory antibodies. Aside from cancer treatment, genetically engineered single strains are also in clinical trials for other indications including diabetes (NCT03751007), oral mucositis (NCT03234465), and rare metabolic disorders (NCT04534842). While microbe-based therapies are still in their infancy, preclinical efforts to uncover a deeper understanding of the links between the gut microbiome, cancer, and the immune system may lead to their expansion and utility in the clinic.

### 5 | MAIN CHALLENGES

The success of cell therapies will rely on the development of solutions to address critical translational challenges. Here, we focus our discussion on common translational barriers faced by the majority of cell therapies including (i) biological challenges, (ii) manufacturing challenges, and (iii) regulatory challenges. We also briefly highlight some specific, unique considerations for certain classes of cell therapy such as CAR-T.

### 5.1 | Biological challenges

There are many common challenges related to the biological activity of cell therapies. These include safety, functional heterogeneity, the
| Cell type          | GM   | Source                          | Indication                                                                 | Name (Sponsor)                     | Route | Accompanying therapies                                                                 | Trial number          | Other trials and/or notes                        |
|--------------------|------|---------------------------------|-----------------------------------------------------------------------------|-----------------------------------|-------|----------------------------------------------------------------------------------------|-----------------------|--------------------------------------------------|
| Blood disorders (n = 17) |      |                                 |                                                                             |                                   |       |                                                                                        |                       |                                                  |
| RBC                | No   | Allogeneic                      | Anemia                                                                      | N/A (St. Justine Hospital Center) | IV    | None                                                                                    | NCT03871244 (Phase 3) | None                                            |
| Metabolic disorders (n = 3) |      |                                 |                                                                             |                                   |       |                                                                                        |                       |                                                  |
| RBC                | No   | Allogeneic                      | Glucose transporter type 1 deficiency syndrome                              | N/A (University of Texas Southwestern Medical Center) | IV    | Glucose transporter 1 (GLUT-1), expressed endogenously on donor RBCs                    | NCT04137692 (Early Phase 1) | None                                            |
| RBC                | No   | Autologous                      | Mitochondrial neurogastrointestinal encephalomyopathy                      | EE-TP (St. George’s, University of London) | IV    | E. coli thymidine phosphorylase, encapsulated in RBC                                  | NCT03866954 (Phase 2) | None                                            |
| RBC                | Yes  | Allogeneic                      | Phenylketonuria                                                             | RTX-134 (Rubius Therapeutics)    | IV    | AvPAL (Anabaena variabilis phenylalanine ammonia lyase), expressed intracellularly     | NCT04110496 (Phase 1) | None                                            |
| Cancer (n = 4)     |      |                                 |                                                                             |                                   |       |                                                                                        |                       |                                                  |
| RBC                | No   | Allogeneic                      | Triple negative breast cancer                                              | Eryaspase (ERYtech Pharma)       | IV    | L-asparaginase, encapsulated in RBC                                                    | NCT03674242 (Phase 2/3) | NCT01518517 (Phase 2/3) |
| RBC                | No   | Unknown                         | Non-small cell lung cancer                                                  | N/A (State Key Laboratory of Respiratory Disease) | IV    | P. vivax parasite, via infection of RBC                                               | NCT02786589 (Phase 1/2) | NCT04165590 (Phase 1/2), NCT03474822 (Phase 1/2), NCT03375983 (Phase 1/2) |
| Infectious diseases (n = 1) |      |                                 |                                                                             |                                   |       |                                                                                        |                       |                                                  |
| RBC                | No   | Allogeneic                      | Malaria                                                                     | N/A (University of Oxford)       | IV    | P. vivax parasite, via infection of RBC                                               | NCT03797989 (Early Phase 1) | None                                            |
| Other (n = 4)      |      |                                 |                                                                             |                                   |       |                                                                                        |                       |                                                  |
| RBC                | No   | Autologous                      | Ataxia telangiectasia                                                       | EryDex (Erydel)                  | IV    | Dexamethasone sodium phosphate, encapsulated in RBC                                   | NCT03563053 (Phase 3) | None                                            |
| Trauma (n = 4)     |      |                                 |                                                                             |                                   |       |                                                                                        |                       |                                                  |
| Platelet           | No   | Allogeneic                      | Surgical blood loss, hemorrhage                                            | N/A (Australian and New Zealand Intensive Care Research Centre) | IV    | None                                                                                    | NCT03991481 (Phase 3) | Efficacy and safety of cryopreserved vs. liquid platelets |
| Blood disorders (n = 3) |      |                                 |                                                                             |                                   |       |                                                                                        |                       |                                                  |
| Platelet           | No   | Allogeneic                      | Thrombocytopenia associated with hematological malignancies                | N/A (Emory University)           | IV    | None                                                                                    | NCT02074436 (Phase 2) | Comparison to epsilonaminocaproic acid (EACA) |

Abbreviation: Routes: IV, intravenous.
| GM Sub-type | Cell modifications | Source | Indication | Name (Sponsor) | Route | Accompanying therapies | Trial number | Other trials and/or notes |
|-------------|--------------------|--------|------------|---------------|-------|------------------------|--------------|---------------------------|
| Consortia for Gut Microbiota (n = 20) | No Donor derived bacterial spores | UMC | Clostridium difficile infection | CP101 (Finch Therapeutics) | Oral | None | NCT03110133 (Phase 2) | NCT03497806 (Phase 2), NCT04182633 (Phase 2) |
| | No Donor derived bacterial spores | UMC | Clostridium difficile infection | SER-109 (Seres Therapeutics) | Oral | None | NCT03183128 (Phase 3) | NCT03183141 (Phase 3) |
| | No Donor derived bacterial spores | UMC | Ulcerative colitis | SER-287 (Seres Therapeutics) | Oral | None | NCT03759041 (Phase 2) | NCT03817125 (Phase 1) |
| | No Donor derived bacterial spores | N/A | Clostridium difficile infection | RBX7455 (Mayo Clinic/Rebiotix Inc.) | Oral | None | NCT02981316 (Phase 1) | NCT04139993 (Phase 1), NCT04155099 (Phase 2) |
| | No Donor derived bacterial spores | N/A | Advanced or metastatic cancer | VE800 (Vedanta Biosciences/Bristol-Myers Squibb) | Oral | (co) Nivolumab | NCT04208958 (Phase 1/2) | NCT03936998 (Phase 1/2) |
| | No Donor derived bacterial spores | N/A | Clostridium difficile infection | VE303 (Vedanta Biosciences) | Oral | None | NCT03788434 (Phase 2) | None |
| | No Donor derived bacterial spores | DMC | Obesity/hypertriglyceridemia | MET 5 (NuByota) | Oral | None | NCT04507971 (Phase 1) | NCT04507971 (Phase 1), NCT03832400 (Phase 1), NCT03686202 (Phase 1) |
| Single microbes for gut microbiota (n = 10) | Yes Bacteria (Lactococcus lactis) | Engineered strain | Diabetes mellitus, type 1 | AG019 (Precigen Actobio) | Oral | (co) Teplizumab | NCT03751007 (Phase 1b/2a) | None |
| | Yes Bacteria (Escherichia coli Nissle 1917) | Engineered strain | Phenylketonuria | SYN1618 (Synlogic) | Oral | None | NCT04534842 (Phase 2) | None |
| | No Bacteria (Enterococcus/N/A galinarum) | DdSS | Solid tumors | MRx0518 (4D Pharma/Merck & Co.) | Oral | (co) Pembrolizumab | NCT03637803 (Phase 1/2) | NCT03851250 (Phase 1/2), NCT04363372 (Phase 2), NCT04193904 (Phase 1), NCT03934827 (Phase 1) |
| | No Bacteria (Clostridium butyricum) | DdSS | Advanced kidney cancer | CBM588 (City of Hope Medical Center/National Cancer Institute) | Oral | (co) Ipilimumab and nivolumab | NCT03829111 (Phase 1) | NCT03922035 (Phase 1) |
| GM Sub-type Cell modifications | Source | Indication | Name (Sponsor) | Route | Accompanying therapies | Trial number | Other trials and/or notes |
|--------------------------------|--------|------------|---------------|-------|------------------------|--------------|--------------------------|
| Engineered microbes for cancer \(n = 13\) | Yes Bacteria (Salmonella typhimurium) Engineered to secrete Engineered strain VEGFR-2 cDNA | Recurrent glioblastoma | VXM01 (Vaximm/Merck/Pfizer) | Oral | None | NCT03750071 (Phase 1/2) | None |
| | Yes Bacteria (Bifidobacteria longum) Engineered to secrete Engineered strain IL-12 | Solid tumors | bacTRL-IL-12 (IQVIA) IV | None | NCT04025307 (Phase 1) | None |
| | Yes Bacteria (Escherichia coli) Engineered to express STING agonist-producing enzymes Engineered strain | Metastatic solid neoplasm, lymphoma | SYN1891 (Synlogic/ IQVIA) (co) Atezolizumab | IT | NCT04167137 (Phase 1) | None |
| | Yes Bacteria (Listeria monocytogenes) Engineered to secrete Engineered strain antigen-adjuvant fusion protein for HPV | Cervical cancer | ADXS11-001 (Advaxis/Gynecologic Oncology Group) | IT | NCT02853604 (Phase 3) | NCT029291055 (Phase 1/2), NCT02002182 (Phase 2) |
| | Yes Bacteria (Listeria monocytogenes) Engineered to secrete Engineered strain patient-specific neoantigens | Metastatic cancer | ADXS-NEO (Advaxis) IT | None | NCT03205080 (Phase 1) | NCT03847519 (Phase 1/2), NCT02325557 (Phase 1/2) |
| | Yes Bacteria (Lactococcus lactis) Engineered to secrete Engineered strain Trefoil Factor 1 | Oral mucositis | AG013 (Oragenics) Oral rinse | None | NCT03234465 (Phase 2) | None |

| Microbes for other applications \(n = 6\) | No Bacteria (Lactobacillus crispatus CTV-05) | Recurrent urinary tract infections | LACTIN-V (University Suppository of Washington) | None | NCT03151967 (Phase 2/3) | NCT03992534 (Phase 1) |
|--------------------------------|--------|----------------------------|-----------------------------|-------|------------------------|--------------|--------------------------|
| | No Bacteria (Nitrosomonas eutropha) | Acne vulgaris | B244 (AOBiome) Topical spray | None | NCT02832063 (Phase 2) | NCT04490109 (Phase 2) |

Abbreviations: Cell Modifications: HPV, human papillomavirus; IL, interleukin; VEGFR, vascular endothelial growth factor receptor; STING, stimulator of interferon response cGAMP interactor. Sources: DMC, defined microbe consortia; DdSS, donor-derived single strain; UMC, undefined microbe consortia. Routes: IV, intravenous; IT, intratumoral.
maintenance of desired biological functions in vivo, and targeted delivery.

5.1.1 Safety and immunogenicity

Safety limitations associated with the cell source, namely immunogenicity, are an important consideration for allogeneic therapies. This challenge is most prominent for stem cells, especially HSCs, as GvHD remains a substantial challenge in HSCT and is a major contributor to graft failure. Many HSCT post-treatments, usually small molecules and biologics, are being investigated to prevent GvHD. Some novel agents that have progressed to Phase 3 trials include alpha-1 antitrypsin (NCT04167514), vedolizumab (NCT03657160), and CD24Fc (NCT04095858). In addition, a combination cell therapy that uses mesenchymal stromal cells to control GvHD has also progressed to Phase 3 (NCT04629833). While immunosuppression can effectively reduce host alloreactivity, this leaves the patient susceptible to viral infections, which can induce graft-associated morbidity and mortality. Notably, adoptive transfer of VSTs is currently being investigated to control viral infections in immunosuppressed patients. For example, transplant donor-derived cytotoxic T lymphocytes (CTLs) are being investigated for the treatment of transplant-related CMV in a Phase 4 trials (NCT03004261), where the cells are primed ex vivo with CMV antigen peptides before administration. The risk of GvHD is also a significant challenge for the translation of many allogeneic immunotherapies, such as T cells and DCs. On the other hand, NK cell therapy is commonly conducted using donor cells. Allogeneic NK cells do not directly induce GvHD because their cytotoxic activities are dampened by inhibitory receptors on healthy cells; therefore, they are usually associated with only minimal immunogenicity. Despite the aforementioned challenges, allogeneic therapies provide a major advantage in terms of streamlining manufacturing processes and, for some applications, producing a sufficient dose. As a result, allogeneic cells are being investigated in clinical trials covering all the cell types mentioned here. For example, in the T-cell field, allogeneic CAR-T therapy has the potential to decrease patient-to-patient heterogeneity, shorten waiting times, and reduce costs, thereby improving both efficacy and accessibility. We identified 26 trials using allogeneic anti-CD19 CAR-T cells, all of which are presently in Phase 1 or 1/2.

In addition to cell source-related challenges, GM cell therapies encounter additional safety limitations. For therapies in which genetic modifications are used to induce receptor expression, risks to the patient include receptor cross-reactivity, immunogenicity, and elaborated receptor-mediated cytokine signaling processes. Other cells that use editing systems (e.g., CRISPR-Cas9 and zinc finger nucleases) may encounter functional challenges associated with off-target effects. Specifically, cells with GM receptors like CAR- and TCR-T cells may cross-react with host antigens to produce widespread off-target, off-tumor effects, while low-level expression of the target on other tissues can lead to on-target, off-tumor effects. Cytokine release syndrome (CRS) is one major untoward effect of CAR-T therapy. This condition is characterized by an excessive inflammatory signaling cascade, which is initiated by the adoptively transferred cells and potentiated by other immune cells like macrophages. If not rapidly treated, CRS leads to shock, neurotoxicity, and potentially organ failure and death. The incidence of CRS among patients receiving FDA-approved CAR-T therapy remains high, with rates greater than 50% and as high as 90% reported for Kymriah® and Yescarta®, respectively. CAR-NK cells may face similar challenges, although their in vivo persistence is shorter than that of CAR-T cells. To address CRS, additional nonreceptor genetic modifications are currently being explored to selectively eliminate adoptively transferred cells. For example, CAR-T cells engineered with a “suicide gene” can display a molecule on their surface that specifically binds an intravenously administered cytotoxic prodrug, thereby enabling selective and tunable depletion of the CAR-T cells in case of intolerable side effects. Specifically, cells have been modified with truncated CD19, truncated epidermal growth factor receptor (EGFR), inducible caspase 9 (iCasp9), and herpes simplex virus thymidine kinase (HSV-TK) suicide genes, among others. This strategy is investigated in clinical trials to prevent both CRS in the treatment of liquid and solid cancers (NCT03016377, NCT04377932) and GvHD in patients who have received HSCT (NCT00914628). For this strategy to be successful, more information is needed about the clinical parameters that warrant a prodrug infusion and the anti-tumor efficacy postadministration.

Additional strategies for the fine-tuning of CAR-T functionality are currently being explored in the preclinical sphere. Many of these involve the use of inducible vectors, such as small molecules, light, and hypoxia, to control the presentation of functional CARs. For example, an inducer may switch on CAR-T function by regulating CAR expression or promoting receptor dimerization. Alternatively, they may disable the cells by triggering CAR degradation. These strategies enable the dampening of overactive cells without the need to induce apoptosis, which represents a key improvement over the suicide gene systems currently used in the clinic. Logic gating is a distinct strategy that uses a combinatorial antigen-targeting design to prevent the CAR-T cells from becoming activated in healthy tissues, which may express low levels of the main target antigen. Instead, cytotoxic functions are only induced in cancerous tissues that over-express a second ligand. This strategy has shown preclinical success in cases where antigen-expressing tumor and healthy cells are spatially separated. In the future, these controllable systems may have the potential to abrogate serious toxicities while maintaining anti-tumor efficacy in patients.

5.1.2 Functional heterogeneity

Maintaining and tuning cell functionality in vivo is also a major biological challenge, especially for cells in the immunotherapy space. One general limitation is functional heterogeneity, which introduces batch-to-batch variation in the product and therefore patient-to-patient variation in the functional response. These factors add to the complexity of treating heterogeneous disease microenvironments that exist within each patient. As a result, outcomes observed in clinical trials
can be highly variable. These inconsistencies make it difficult to assess translational potential and properly identify which patients might ben-
efit the most from therapy. MSCs in particular are impacted by these
discrepancies, with differences in donor sources, tissue sources, sub-
population isolation procedures, cell storage conditions, and other manu-
ufacturing processes leading to substantial variation both within
and among trials.120,121 Future approaches to address the functional
heterogeneity challenge should consider both the manufacturing and
clinical trial design perspectives. Better characterization and quality
control of cell products during the manufacturing process will be
required to maintain functional homogeneity. In addition, new
manufacturing strategies, such as iPSC-derived cell manufacturing,
should be further explored.122 Finally, clinical trial design will need to
include more comprehensive, standardized documentation of the
properties of injected cells. Using these data, cross-analyses of the
relationships between cell identities/properties and safety/efficacy
may be better performed to identify key attributes and inform future
directions.

5.1.3 | Maintenance of biological activities

The efficacy of cell therapies is highly dependent on the ability of cells
to retain functionality in an in vivo context. Changes in the function
of living cells post-administration, such as exhaustion and inadequate
persistence, are barriers for many therapies including T cells, DCs, and
NK cells. Solutions to these challenges are often complex, as simply
altering the cell dose may not be feasible due to manufacturing and
safety limitations. Approaches such as ex vivo cell preconditioning
and combination therapy are relevant for many types of cells and are
being actively explored in clinical trials. For example, MSCs can be
pretreated with cytokines, small molecules, hypoxia, and/or biomate-
rials to tune their functionality according to the desired applica-
tion.47,123 For example, MSC preconditioning in a hypoxic
environment has been shown to upregulate genes associated with
survival, leading to improved persistence.123 Similarly, NK cell efficacy
is reliant upon sufficient ex vivo expansion in the presence of
cytokines such as IL-2 and IL-15. However, this approach is a double-
edged sword, as these cells may develop a dependency on this envi-
nronment and later become exhausted or die via apoptosis in vivo.124
One novel expansion method is the incubation of cytotoxic NK cells
with “feeder” NK cells containing membrane-bound stimulatory cyto-
kines. This approach enables the expansion of a sufficient dose from
a single small-volume blood draw, eliminating the need for a donor
product (NCT02809092). Many NK cell clinical trials also employ
combination therapies to either sustain NK cell function directly or
synergize with the therapy. For example, anti-tumor antibodies may
improve NK cell retention in solid tumors, while co-administered cyto-
kines help maintain cytotoxic activities. Synergistic effects have been
observed with the co-administration of NK cells and checkpoint
blockade antibodies (NCT03958097). Likewise, the biological activity
of DC therapies is dependent on multiple factors including the matu-
ration process, source, loading method, and antigen target(s). DC
therapies may also benefit from combination approaches to overcome
immunosuppressive microenvironments and enhance in vivo activity.
For instance, the administration of proinflammatory cytokines and
Toll-like receptor (TLR) agonists at the injection site has proven effec-
tive for the enhancement of DC migration into the lymph nodes.125

Similar to NK cells and DCs, T cells have also benefited from com-
bination strategies, especially checkpoint blockade and low-dose IL-2.
CAR-T cells in particular have demonstrated improved activation and
persistence with the incorporation of immunomodulatory features via
genetic modification. The addition of costimulatory domains to the intra-
cellular portion of the CAR was one of the earliest approaches used to
prevent cell exhaustion induced by chronic stimulation with the target
antigen. More recently, the secretion or display of therapeutic payloads
directly from the delivered cells has emerged as a promising approach in
the clinical landscape.126 There are many current trials employing CAR-T
cells that have been modified to display or secrete (i) checkpoint inhibi-
tors to prevent T-cell exhaustion or (ii) cytokines (e.g., IL-15, IL-12, IL-7)
to promote T cell persistence and proliferation in an autoregulatory man-
ner. In the treatment of solid tumors, these cytokines can also promote a
Th1 environment to overcome immunosuppression.110,127 Two of these
trials have progressed to Phase 2, one with cells that secrete a mutant
PD-1 fusion protein (NCT04162119), and another with cells that secrete
IL-7 and CCL19 (NCT03929107). Comparable genetic modifications
have also been used in the stem cell field, albeit less frequently. For
example, MSCs have been engineered to express therapeutic payloads
like the cytokine TRAIL (NCT03298763). While GM cells are modified to
secrete or express a payload, non-GM cells have also been used as drug
delivery vehicles and seen some successes in preclinical settings. In such
cases, therapeutic cells can carry nano- or micro-scale biomaterials that
contain stimulatory molecules such as cytokines. This particular strategy,
also called cytokine backpacking, has potential to offer a versatile alterna-
tive to genetic modification in the clinical setting.128-130 Currently, there
is a Phase 1 trial underway for the use of IL-15 superagonist-loaded
T cells in the treatment of solid and liquid cancers (NCT03815682).

5.1.4 | Delivery challenges

Targeted delivery is another biological challenge for many cell thera-
pies, particularly those designed to treat diseases in solid tissues. Both
cell migration to and localization at the target site are important con-
siderations, and these factors may depend heavily on the initial deliv-
ery route. For example, intravenously administered T cells must sense
biological cues, such as chemokine gradients and endothelial markers,
to extravasate into a solid tumor. One major approach that is being
explored to improve delivery is altering the administration route.
CAR-T cells indicated for solid cancers are currently administered via
a variety of routes (see Section 4) to accomplish direct delivery into
target tissue, a nearby artery, or cerebrospinal fluid (for neurologic
tumors). New NK cell administration routes, including intracranial and
intratumoral, are also being explored for the treatment of glioblastoma
(NCT03383978, NCT04489420). While T and NK cells must reach the
site of a tumor or infection, DCs must reach the lymph nodes to
execute their antigen-presenting functions. Injection routes including intradermal, intranodal, and subcutaneous are currently being explored to improve lymph node trafficking.\textsuperscript{131} For HSCs, intra-bone infusions are currently being explored as an alternative to IV administration to speed HSC delivery and graft reconstitution in the bone marrow.\textsuperscript{132} While the outcomes of this approach are not yet conclusive, this administration route may reduce acute GvHD, providing a solution to this longstanding biological challenge.

5.2 Manufacturing challenges

The development of closed, automated manufacturing processes is a necessary yet challenging endeavor for the production of safe, high-quality cell therapies. Current barriers and advancements related to the manufacturing of cell therapies have been reviewed in detail elsewhere.\textsuperscript{14,133,134} Briefly, the major steps in the manufacture of a relatively complex cell therapy (e.g., an autologous GM cell therapy) are as follows. First, the cells are extracted from the patient and shipped to the site of manufacture, where relevant populations are isolated. Cells are activated, genetically modified, and expanded before undergoing post-processing, such as washing and purification. As more patient data becomes available, heightened attention should be paid to the consequences of impurities in cell therapy products. Although adverse events are rare, in one documented circumstance, the errant transduction of a single B cell with a CAR rendered CAR-T therapy (Kymriah) ineffective.\textsuperscript{135} After samples are taken for quality assurance (QA) measures, the cells are concentrated and packaged by dose before being shipped to the site where the therapy will be administered.\textsuperscript{133} The process for allogeneic manufacturing is streamlined by the exclusion of the first extraction and shipping steps. Multiple challenges exist at each step in this workflow, though future technologies have shown promise for potential integration into a closed, automated process. Current areas of focus include cryopreservation, cell selection and activation workflows, automated batch monitoring for QA purposes, and the adoption of electronic records systems.\textsuperscript{126,134,136} These interventions have the potential to decrease the heterogeneity of cell therapies and reduce production time. In the future, decentralization of the manufacturing process will expand the global scale of cell therapies to reach patients who are currently inaccessible.

Another closely related factor is the cost associated with developing, manufacturing, and distributing cell therapies. The steep price tags of some therapies, such as CAR-T therapy Kymriah's list price of $475,000,\textsuperscript{137} have drawn criticism due to concerns about patient accessibility. Advances in manufacturing procedures, particularly automation, along with widespread adoption of allogeneic therapies may help drive down direct costs in the future.

5.3 Regulatory challenges

In addition to the aforementioned considerations, future advancements in the clinical translation of cell therapies will rely on the development of industry-wide and regulatory approval standards. As of 2020, there is no universal system for the classification of cell therapies. Not only does this insufficiency impede the regulatory approval process, but it also allows for a substantial degree of ambiguity in the reporting of quality attributes and clinical outcomes.\textsuperscript{138} In light of these concerns, the FDA released a warning regarding the dangers of unapproved stem-cell therapies in 2020.\textsuperscript{139} Notably, regulatory standards related to product purity are rapidly changing in the more recently developed field of microbe-based therapy. In early 2020, alerts were issued regarding the risks of transmission of pathogenic microorganisms and SARS-CoV-2 via FMT.\textsuperscript{140} Given the rapid emergence of many new cell therapies with novel features, it is imperative that products be categorized in a central location for the benefit of the research, medical, and patient communities. In addition, this endeavor will enable more comprehensive future studies to identify associations between cell properties and clinical efficacy. These studies may then inform decision-making at the regulatory, clinical, and preclinical levels to accelerate the development of novel therapies. Eventually, these efforts may enable the standardization of critical quality attributes, which has the potential to streamline the development and approval processes.

6 Conclusion

Cells as living entities have unique properties and are being leveraged as potent therapies to treat diseases in a way that conventional therapies cannot. Many cell therapies have been approved by the FDA, EMA, and other regulatory agencies around the world for the treatment of many diseases. Particularly, many of these approved products have demonstrated promising efficacy in treating diseases that were thought to be incurable by conventional therapies, such as CAR-T therapy for B-cell malignancies. Great efforts are also being devoted to further expanding the clinical application of these approved products in other indications. In addition, with improved understanding of the biology of different living cells, the clinical landscape is seeing a number of clinical trials investigating newer types of cell therapies like microbes. These efforts are not only focusing on exploring more types of cells that have unique biological functions, but further expanding the spectrum of indications cell therapies can treat. Still, cell therapies are in their early stages of development and face biological, manufacturing, and regulatory challenges that affect their clinical translation. Solving these challenges will need to involve united efforts including further fundamental biological studies, standardized clinical listing and data sharing protocols, and automated, decentralized manufacturing capabilities. However, with its proven clinical success and ongoing clinical advances, cell therapy remains a highly active area of research and more disruptive cell therapy products are expected to emerge in the near future.

Acknowledgments

Neha Kapate was supported by the National Science Foundation Graduate Research Fellowship under Grant No. 1122374. Morgan
E. Janes was supported by the National Science Foundation Graduate Research Fellowship under Grant No. 1745302. The research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R35GM137898 (to Aaron C. Anselmo). Samir Mitragotri acknowledges support from the National Institutes of Health (1R01HL143806-01) and Defense Medical Research and Development Program by the Department of Defense (W81XWH-19-2-0011). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding organizations. Schematic representations were generated with the support of Biorender (©BioRender – biorender.com) and Servier Medical Art (smart.servier.com).

**AUTHOR CONTRIBUTIONS**

Li Wen Wang: Data curation; formal analysis; investigation; visualization; writing-original draft; writing-review & editing. Morgan Janes: Conceptualization; formal analysis; methodology; visualization; writing-original draft; writing-review & editing. Ninad Kumbhojkar: Conceptualization; formal analysis; writing-original draft; writing-review & editing. Neha Kapate: Data curation; formal analysis; writing-original draft; writing-review & editing. Samir Mitragotri: Conceptualization; funding acquisition; writing-review & editing. John Clegg: Data curation; formal analysis; writing-original draft; writing-review & editing. Supriya Prakash: Formal analysis; methodology; visualization; writing-original draft. Mairead Heavey: Formal analysis; writing-original draft. zongmin Zhao: Conceptualization; formal analysis; methodology; writing-original draft; writing-review & editing. Aaron Anselmo: Conceptualization; data curation; formal analysis; funding acquisition; visualization; writing-original draft; writing-review & editing. Samir Mitragotri: Conceptualization; funding acquisition; writing-review & editing.

**ORCID**

Lily Li-Wen Wang [https://orcid.org/0000-0002-0297-9553](https://orcid.org/0000-0002-0297-9553)
Neha Kapate [https://orcid.org/0000-0003-4576-0014](https://orcid.org/0000-0003-4576-0014)
Supriya Prakash [https://orcid.org/0000-0003-0772-8822](https://orcid.org/0000-0003-0772-8822)
Aaron C. Anselmo [https://orcid.org/0000-0003-3290-7857](https://orcid.org/0000-0003-3290-7857)
Samir Mitragotri [https://orcid.org/0000-0002-2459-8305](https://orcid.org/0000-0002-2459-8305)

**REFERENCES**

1. Fischbach MA, Bluestone JA, Lim WA. Cell-based therapeutics: the next pillar of medicine. *Sci Transl Med.* 2013;5(179): 179ps7.
2. Zhao Z, Ukidve A, Kim J, Mitragotri S. Targeting strategies for tissue-specific drug delivery. *Cell.* 2020;181(1):151-167.
3. Anselmo AC, Mitragotri S. Cell-mediated delivery of nanoparticles: taking advantage of circulatory cells to target nanoparticles. *J Control Release.* 2014;190:531-541.
4. Riglar DT, Silver PA. Engineering bacteria for diagnostic and therapeutic applications. *Nat Rev Microbiol.* 2018;16(4):214-225. [https://doi.org/10.1038/nrmicro.2017.172](https://doi.org/10.1038/nrmicro.2017.172).
5. Bailey SR, Maus MV. Gene editing for immune cell therapies. *Nat Biotechnol.* 2019;37(12):1425-1434.
6. Seimetz D, Heller K, Richter J. Approval of first CAR-Ts: have we solved all hurdles for ATMPs? *Cell Med.* 2019;11:2155179018822781.
7. Gharabeh B, Anderson JE, Deasy BM. Combating the threat of stem cell tourism through patient education and government regulation. *Innov Entrepen Health.* 2016;3:15.
8. Gottipamula S, Bhat S, Seetharam RN. Mesenchymalstromal cells: basics, classification, and clinical applications. *J Stem Cells.* 2018;13(1):23-47.
9. AVITA Medical. RECELL®: About RECELL® System. [https://recellsystem.com/about-recell-system](https://recellsystem.com/about-recell-system) Accessed October 28, 2020.
10. Zaulyanov L, Kirsner RS. A review of a bi-layered living cell treatment (Apigraf®) in the treatment of venous leg ulcers and diabetic foot ulcers. *Clin Interv Aging.* 2007;2(1):93-98.
11. Basad E, Ishaque B, Bachmann G, Stürz H, Steinmeyer J. Matrix-induced autologous chondrocyte implantation versus microfracture in the treatment of cartilage defects of the knee: a 2-year randomised study. *Knee Surg Sports Traumatol Arthrosc.* 2010;18(4):519-527.
12. Shevchenko RV, James SL, James SE. A review of tissue-engineered skin bioconstructs available for skin reconstruction. *J Roy Soc Interface.* 2010;7(43):229-258.
13. Huang BJ, Hu JC, Athanasiou KA. Cell-based tissue engineering strategies used in the clinical repair of articular cartilage. *Biomaterials.* 2016;98:1-22.
14. Heathman TR, Nienow AW, McCall MJ, Coopman K, Kara B, Hewitt CJ. The translation of cell-based therapies: clinical landscape and manufacturing challenges. *Regen Med.* 2015;10(1):49-64.
15. Klein HG, Anstee DJ. Mollisori’s Blood Transfusion in Clinical Medicine. New Jersey, NJ: John Wiley & Sons; 2014.
16. Brentjens RJ, Latouche J-B, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. *Nat Med.* 2003;9(3):279-286.
17. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. *Sci Transl Med.* 2011;3(95):95ra73.
18. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. *N Engl J Med.* 2011;365:725-733.
19. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. *Nat Rev Cancer.* 2003;3(1):35-45.
20. Chaplin DD. Overview of the immune response. *J Allergy Clin Immunol.* 2010;125(2):S3-S23.
21. Abel AM, Yang C, Thakar MS, Malarakannan S. Natural killer cells: development, maturation, and clinical utilization. *Front Immunol.* 2018;9:1869.
22. Gardner A, Ruffell B. Dendritic cells and cancer immunity. *Trends Immunol.* 2016;37(12):855-865.
23. Yu H, Tian Y, Wang Y, Mineishi S, Zhang Y. Dendritic cell regulation of graft-vs-host disease: immunostimulation and tolerance. *Front Immunol.* 2019;10:93.
24. Kratofil RM, Kubes P, Deniset JF. Monocyte conversion during inflammation and injury. *Arterioscler Thromb Vasc Biol.* 2017;37(1):35-42.
25. Kumar V. Macrophages: the Potent Immunoregulatory Innate Immune Cells. *Macrophage at the Crossroads of Innate and Adaptive Immune Cells.* London, England: IntechOpen; 2019.
26. Lee AF, Mahler N, Best C, Lee Y-U, Breuer CK. Regenerative implants for cardiovascular tissue engineering. *Transl Res.* 2014;163(4):321-341.
27. Kuhn V, Diedrich L, Keller TS IV, et al. Red blood cell function and dysfunction: redox regulation, nitric oxide metabolism, anaemia. *Antioxid Redox Signal.* 2017;26(13):718-742.
28. Holinstat M. Normal platelet function. *Cancer Metastasis Rev.* 2017;36(2):195-198.
29. Chabannon C, Kuball J, Bondanza A, et al. Hematopoietic stem cell transplantation in its 60s: a platform for cellular therapies. Sci Transl Med. 2018;10(436):1-9.

30. Hutt D. Engraftment, graft failure, and rejection. The European Blood and Marrow Transplantation Textbook for Nurses. Cham: Springer; 2018:259-270.

31. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Controlled Release. 2004;100(1):5-28. https://doi.org/10.1016/j.jconrel.2004.08.010.

32. Ullah I, Subbarao RB, Rho GJ. Human mesenchymal stem cells: current trends and future prospective. Biosci Rep. 2015;35(2).

33. Vargason AM, Anselmo AC. Clinical translation of microbe-based therapies: current clinical landscape and preclinical outlook. Bioeng Transl Med. 2018;3(2):124-137.

34. National Cancer Institute. CAR T Cells: engineering patients’ immune cells to treat their cancers. https://www.cancer.gov/about-cancer/treatment/research/car-t-cells Accessed October 22, 2020.

35. Jayaraman J, Melody MP, Hou AJ, et al. CAR-T design: elements and their synergistic function. EBioMedicine. 2020;58:102931.

36. Rodríguez-Cartagena LG, Bowles BS, Kurani SS, Windebank AJ, Kenderian SS, Greenberg-Worsiek AJ. Chimeric antigen receptor T-cells: successful translation of the first cell and gene therapy from bench to bedside. Clin Transl Sci. 2018;11(6):537-539.

37. Novartis. Kymriah/Mechanism of Action. https://www.hcp.novartis.com/products/kymriah/diffuse-large-b-cell-lymphoma/adults/mechanism-of-action/ Accessed October 22, 2020.

38. Gilead. YESCARTA. https://www.yescarta.com/ Accessed October 22, 2020.

39. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 2000;356(9232):802-807.

40. Lee JH, Lee J-H, Lim Y-S, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology. 2015;148(7):1383-1391.e6.

41. Rocha V, Gluckman E. Clinical use of umbilical cord blood hematopoietic stem cells. Biol Blood Marrow Transplant. 2006;12(1):34-41.

42. Gluckman E, Rocha V, Bayer-Chammard A, et al. Outcome of cordblood transplantation from related and unrelated donors. N Engl J Med. 1997;337(6):373-381.

43. Lee JH, Lee J, Jung S, et al. Mesenchymal stem cell and immune-modulation: current status and future prospects. Cell Death Dis. 2016;7(1):e2062.

44. Zhu H, Yu B, Yang J. Exogenous and endogenous stem cells for skeletal regeneration. Stem Cells Int. 2018;2018:1-2.

45. Levy O, Kuai R, Siren EM, et al. Shattering barriers toward clinically meaningful MSC therapies. Sci Adv. 2020;6(30):eaab6884.

46. Park YB, Ha CW, Lee CH, Yoon YC. Cartilage regeneration in osteoarthritic patients by a composite of allogeneic umbilical cord blood-derived mesenchymal stem cells and hyaluronate hydrogel: results from a clinical trial for safety and proof-of-concept with 7 years of extended follow-up. Stem Cells Transl Med. 2017;6(2):613-621.

47. Scott LJ. Darvadstrocel: a review in treatment-refractory complex perianal fistulas in Crohn’s disease. BioDrugs. 2018;32(6):627-634.

48. Kurtzberg J, Abdel-Azm H, Carpenter P, et al. A phase 3, single-arm, prospective study of remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant. 2020;26:845-854.

49. Levy O, Kuai R, Siren EM, et al. Shattering barriers toward clinically meaningful MSC therapies. Sci Adv. 2020;6(30):eaab6884.

50. Kurtzberg J, Abdel-Azm H, Carpenter P, et al. A phase 3, single-arm, prospective study of remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant. 2020;26:845-854.

51. Cheever MA, Higano CS. PROVENGE (sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic vaccine. J Clin Cancer. 2011;17(11):3520-3526.

52. Snits LP, Bouter KE, de Vos WM, Borody TJ, Nieuworp M. Therapeutic potential of fecal microbiota transplantation. Gastroenterology. 2013;145(5):946-953.

53. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011;9(12):1044-1049.

54. Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2014;8(12):1569-1581.

55. Kelly CR, Kahn S, Kashyap P, et al. Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology. 2015;149(1):223-237.

56. Fuller R. Probiotics in man and animals. J Appl Bacteriol. 1989;66(5):365-378.

57. Williams NT. Probiotics. Am J Health Syst Pharm. 2010;67(6):449-458.

58. Suez J, Zmora N, Segal E, Elinav E. The pros, cons, and many unknowns of probiotics. Nat Med. 2019;25(5):716-729.

59. O’Toole PW, Marchesi JR, Hill C. Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. Nat Microbiol. 2017;2(5):1-6.

60. van der Schans JJ, Van De Donk NW, Mutis T. Dual targeting to overcome current challenges in multiple myeloma CAR T-cell treatment. Front Oncol. 2020;10:1362.

61. Harris DT, Kranz DM. Adoptive T cell therapies: a comparison of T cell receptors and chimeric antigen receptors. Trends Pharmacol Sci. 2016;37:220-230.

62. Kakarla S, Gottschalk S. CAR T cells for solid tumors: armed and ready to go? Cancer J. 2014;20(2):151-155.

63. Xu Y, Yang Z, Horan LH, et al. A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta TCR signaling to facilitate T-cell cytotoxicity with low cytokine release. Cell Discovery. 2018;4(1):62-62.

64. Qian C, Wang Y, Reppel L, et al. Viral-specific T-cell transfer from HSC donor for the treatment of viral infections or diseases after HSCT. Bone Marrow Transplant. 2018;53(2):114-122.

65. Pfaff C, Vo LT, Bluestone JA. Treg cell-based therapies: challenges and perspectives. Nature Rev Immunol. 2020;20(3):158-172.

66. Thomas ED, Locht HE, Li WC, Ferree JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med. 1957;257(11):491-496.

67. Bazinet A, Popradi G. A general practitioner’s guide to hematopoietic cell transplantation. Curr Oncol. 2019;26(3):187-191.

68. Gyorkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014;124(3):344-353.

69. Sengsayadeth S, Savani BN, Biaise D, Malard F, Nagler A, Mohty M. Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission—a review from the Acute Leukemia Working Party of the EBMT. Haematologica. 2015;100(7):859-869.

70. Pinho S, Frenette PS. Haematopoietic stem cell activity and interactions with the niche. Nat Rev Mol Cell Biol. 2019;20(5):303-320.

71. DiGiusto DL, Krishnan A, Li L, et al. RNA-based gene therapy for HIV with lentiviral vector—modified CD34+ cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med. 2010;2(36):36ra43.

72. Bryukhovetskiy IS, Dyuizen IV, Shevchenko VE, et al. Hematopoietic stem cells as a tool for the treatment of glioblastoma multiforme. Mol Med Rep. 2015;26:845-854.
74. Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824-833.
75. Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol. 2018;14(8):493-507.
76. English K. Mechanisms of mesenchymal stromal cell immunomodulation. Immuln Cell Biol. 2013;91(1):19-26.

77. Kode JA, Mukherjee S, Joglekar MV, Hardikar AA. Mesenchymal stem cells: immunobiology and role in immunomodulation and tissue regeneration. Cytotherapy. 2009;11(4):377-391.
78. Yagi H, Soto-Gutierrez A, Parekkadan B, et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci. 2009;106(12):4822-4827.
79. Matuskova M, Baranovicova L, Kozovska Z, et al. Intrinsic properties of tumour cells have a key impact on the bystander effect mediated by genetically engineered mesenchymal stromal cells. J Gene Med. 2012;14(12):776-787.
80. Niess H, Bao Q, Conrad C, et al. Selective targeting of genetically engineered mesenchymal stem cells to tumor stroma microenvironment using tissue-specific suicide gene expression suppresses growth of hepatocarcinoma. Ann Surg. 2011;254(5):767-775.
81. Suresh SC, Selvaraju V, Thirunavukkarasu M, et al. Thioredoxin-1 (Trx1) engineered mesenchymal stem cell therapy increased pro-angiogenic factors, reduced fibrosis and improved heart function in the infarcted rat myocardium. Int J Cardiol. 2015;201:517-528.
82. Tounson A, McDonald C. Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell. 2015;17(11):1-22.
83. Zakrzewski W, Dobrzyński M, Szymonowicz M, Rybak Z. Stem cells: past, present, and future. Stem Cell Res. Therapy. 2019;10:1-22.
84. Cheng M, Chen Y, Xiao W, Sun R, Tian Z. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol. 2013;10(3):230-252.
85. Siegel EL, Zhu Y, Wang P, Yang L. Off-the-shelf CAR-NK cells for cancer immunotherapy. Cell Stem Cell. 2018;23(2):160-161.
86. Suck G, Odendahl M, Nowakowska P, et al. NK-92: an off-the-shelf therapeutic for adoptive natural killer cell-based cancer immunotherapy. Cancer Immunol Immunother. 2016;65(4):485-492.
87. Pende D, Falco M, Vitale M, et al. Killer Ig-like receptors (KIRs): their role in NK cell modulation and developments leading to their clinical exploitation. Front Immunol. 2019;10:1179.
88. Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J. CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine. 2020;59:102975.
89. Cappuzzello E, Sommaggio R, Zanovello P, Rosato A. Cytokines for NK cell modulation. Cytokine Growth Factor Rev. 2017;36:99-105.
90. Güttgemann S, Frank S, Strehl J, Schmidt-Wolf IG. Cytokine-induced killer cells are type II natural killer T cells. GMS German Med Sci. 2007;5.
91. Klingemann H, Boissel L, Toneguzzo F. Natural killer cells for immunotherapy—advantages of the NK-92 cell line over blood NK cells. Front Immunol. 2016;7:91.
92. Habif G, Crinier A, André P, Vivier E, Narni-Mancinelli E. Targeting natural killer cells in solid tumors. Cell Mol Immunol. 2019;16(5):415-422.
93. McNemey KO, Karageorgos SA, Hogarty MD, Bassiri H. Enhancing neuroblastoma immunotherapies by engaging INKT and NK cells. Front Immunol. 2020;11:873.
94. Golán I, Rodríguez de la Fuente L, Costoya JA. NK cell-based glioblastoma immunotherapy. Cancers. 2018;10(12):522.
95. Chan MWY, Viswanathan S. Recent progress on developing exogenous monocyte/macrophage-based therapies for inflammatory and degenerative diseases. Cytotherapy. 2019;21(4):393-415.
96. DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19(6):369-382.
97. Lee S, Kivimäe S, Dolor A, Szoka FC. Macrophage-based cell therapies: the long and winding road. J Control Release. 2016;240:527-540.
98. He W, Kapate N, Shields CW IV, Mitragotri S. Drug delivery to macrophages: a review of targeting drugs and drug carriers to macrophages for inflammatory diseases. Adv Drug Deliv Rev. 2019;165:15-40.
99. Hatakeyama M, Kanazawa M, Ninomiya I, et al. A novel therapeutic approach using peripheral blood mononuclear cells preconditioned by oxygen-glucose deprivation. Sci Rep. 2019;9(1):1-14.
100. Khoruts A, Hoffmann DE, Palumbo FB. The impact of regulatory policies on the future of fecal microbiota transplantation. J Law Med Ethics. 2019;47(4):482-504. https://doi.org/10.1177/1073110519897726.
101. Allegretti JR, Fischer M, Sagí SV, et al. Fecal microbiota transplantation capsules with targeted colonic versus gastric delivery in recurrent Clostridium difficile infection: a comparative cohort analysis of high and lose dose. Dig Dis Sci. 2019;64(6):1672-1678. https://doi.org/10.1007/s10620-018-5396-6.
102. Blount KF, Shannon WD, Deych E, Jones C. Restoration of bacterial microbiome composition and diversity among treatment responders in a phase 2 trial of RBX2660: an investigational microbiome restoration therapeutic. Open Forum Infect Dis. 2019;6(4). https://doi.org/10.1093/ofid/ofz095.
103. Cordaill-Simmons M, Rouanet A, Pot B. Live biotherapeutic products: the importance of a defined regulatory framework. Exp Mol Med. 2020;52(9):1397-1406. https://doi.org/10.1080/s12276-020-0437-6.
104. Charbonneau MR, Isabella VM, Li N, Kurtz CB. Developing a new class of engineered live bacterial therapeutics to treat human diseases. Nat Commun. 2020;11(1):1738. https://doi.org/10.1038/s41467-020-15508-1.
105. Mimeo M, Citronik RJ, Lu TK. Microbiome therapeutics - advances and challenges. Adv Drug Deliv Rev. 2016;105:44-54. https://doi.org/10.1016/j.addr.2016.04.032.
106. Peterson CT, Sharma V, Elmén L, Peterson SN. Immune homeostasis, dysbiosis and therapeutic modulation of the gut microbiota. Clin Exp Immunol. 2015;179(3):363-377. https://doi.org/10.1111/cei.12474.
107. Bolland CM, Heslop HE. T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood. 2016;127(26):3331-3340.
108. Miller JS, Geller MA. Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy. 2011;3(12):1445-1459.
109. Jin C, Yu D, Essand M. Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors. Immunotherapy. 2016;8(12):1355-1361. https://doi.org/10.2217/imt-2016-0125.
110. Yáñez L, Sánchez-Escamilla M, Perales MA. CAR T cell toxicity: Current management and future directions. HemaSphere. 2019;3(2).
111. Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. New Engl J Med. 2017;377(26):2545-2554.
112. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544.
113. Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147-167.
114. Sakemura R, Terakura S, Watanabe K, et al. A Tet-On inducible system for controlling CD19-chimeric antigen receptor expression upon drug administration. Cancer Immunol Res. 2016;4(8):658-668.
115. Huang Z, Wu Y, Allen ME, et al. Engineering light-controllable CAR T cells for cancer immunotherapy. Sci Adv. 2020;6(8):eaay9209.
